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"Siehst du, Momo", sagte er dann zum Beispiel, "es ist so: 
Manchmal hat man eine sehr lange Straße vor sich. Man denkt, die ist so schrecklich lang; 
 das kann man niemals schaffen, denkt man."  
  
Er blickte eine Weile schweigend vor sich hin, dann fuhr er fort:  
"Und dann fängt man an sich zu eilen. Und man eilt sich immer mehr. Jedes Mal, wenn man 
aufblickt, sieht man, dass es gar nicht weniger wird, was noch vor einem liegt. 
Und man strengt sich noch mehr an, man kriegt es mit der Angst, und zum Schluss ist man ganz 
außer Puste und kann nicht mehr. Und die Straße liegt immer noch vor einem. 
So darf man es nicht machen."  
  
Er dachte einige Zeit nach. Dann sprach er weiter:  
"Man darf nie an die ganze Straße auf einmal denken, verstehst du? Man muss nur an den 
nächsten Schritt denken, an den nächsten Atemzug, an den nächsten Besenstrich. Und immer 
wieder nur an den nächsten." 
 
Wieder hielt er inne und überlegte, ehe er hinzufügte:  
"Dann macht es Freude; das ist wichtig, dann macht man die Sache gut. Und so soll es sein."  
  
Und abermals nach einer langen Pause fuhr er fort:  
"Auf einmal merkt man, dass man Schritt für Schritt die ganze Straße gemacht hat. Man hat gar 
nicht gemerkt wie, und man ist nicht außer Puste."  
Er nickte vor sich hin und sagte anschließend:  
"Das ist wichtig."  
 
  
 
Beppo Straßenkehrer in „Momo“ von Michael Ende 
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Abstract 
Uridine diphospho (UDP) glucuronosyltransferases (UGTs) catalyze the transfer of a 
sugar moiety from UDP-sugar to endogenous or exogenous compounds. The water 
solubility of these substances is increased thereby and their excretion from the human 
body is facilitated. The resulting glycosides, mostly glucuronides, can be 
pharmacologically relevant and are therefore needed as purified metabolites as reference 
standards or for toxicity studies. In this work, a whole-cell biotransformation system 
using recombinant Schizosaccharomyces pombe for the production of glycosides is 
described. It is based on the coexpression of a single UGT isoform and human UDP 
glucose-6-dehydrogenase, which delivers UDP-glucuronic acid. The system existed for 
UGT1A9 and has been extended in this work to be established now for each of the 19 
human (and one further polymorphic variant of UGT2B7) and one rat isoform. The system 
was applied for different purposes. In one study, the usage of alternative UDP-sugar 
cofactors was investigated and the glucosidation of ibuprofen was shown. Furthermore, 
enhanced glucoside production rates could be obtained by overexpression of the fission 
yeast gene fyu1, which was discovered to act as UDP glucose pyrophosphorylase. 
Investigations of glucuronidation properties of single isoforms and those of different 
functional groups were studied as well. So, the glucuronidation of two substrates, which 
just differed in their functional group, being a hydroxyl group or a thiol, was compared.  
 
 
 VI 
Zusammenfassung 
Uridin-diphospho (UDP) Glukuronosyltransferasen (UGTs) katalysieren den Transfer eines 
Zuckers von UDP-Zucker auf endogene oder exogene Stoffe. Dies erhöht deren 
Wasserlöslichkeit und erleichtert somit ihre Ausscheidung aus dem Körper. Die 
resultierenden Glykoside, meist Glukuronide, können pharmakologisch relevant sein und 
werden als Referenzstandards oder in Toxizitätsstudien benötigt. In dieser Arbeit wird ein 
Ganzzell-Biotransformationssystem mit rekombinanten S. pombe-Zellen für die 
Produktion von Glykosiden beschrieben. Es basiert auf der Koexpression einer einzelnen 
UGT-Isoform mit humaner UDP-Glukose-6-Dehydrogenase, die UDP-Glukuronsäure liefert. 
Das System war bereits im Vorfeld für UGT1A9 etabliert worden und wurde in dieser 
Arbeit erweitert auf alle 19 humane UGT-Isoformen (und eine weitere Variante von 
UGT2B7) sowie eine Ratten-UGT. Es wurde eingesetzt, um den Gebrauch alternativer 
UDP-Zucker Kofaktoren zu untersuchen. So konnte die Glukosidierung von Ibuprofen 
gezeigt werden. Weiter konnte die Glukosid Produktion durch die Überexpression des 
Spalthefe-Gens fyu1 erhöht werden. Dieses fungierte dabei als UDP-Glukose 
Pyrophosphorylase. Untersuchungen von Glukuronidierungs-Eigenschaften von einzelnen 
Isoformen und von verschiedenen funktionellen Gruppen wurden ebenfalls durchgeführt. 
So wurde die Glukuronidierung eines Substrates mit einer durch ein Thiol ersetzten 
Hydroxyl-Gruppe durch verschiedene UGT Isoformen verglichen.  
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1 Introduction 
1.1 Drug metabolism and the role of glucuronides 
Metabolism describes all biochemical procedures, proceeding in the plant, animal or 
human organism or in parts of these, and conducing to the assembly, conversion and 
maintenance of the body substance as well as the maintenance of the body functioning 
(der Brockhaus, 2003). A very important part is the metabolism of xenobiotics including 
drugs. Many of those are lipophilic compounds which accumulate in the human body if 
they are not converted to more water soluble metabolites. If those compounds 
additionally have toxic properties, an accumulation in the human body would be fatal. 
Hence, detoxification mechanisms have developed increasing the water soluble 
properties of foreign compounds which facilitates their elimination mainly via bile or urine 
from the human body. This detoxification process occurs mainly in the liver and is 
schematically classified in two phases. In principle, the molecule is functionalized in 
phase I by the introduction of a functional group, which in turn is conjugated with a 
further molecule moiety in phase II. But this classification nowadays is obsolete to some 
extent, since many molecules are metabolized by conjugation without undergoing a 
phase I process, or in turn, many molecules are already excreted after a phase I reaction. 
Enzymes participating in this detoxification mechanism are shown in Figure 1.  
 
Figure 1: Overview of enzymes participating in phase I and phase II of human drug metabolism. The 
percentage of phase I and phase II metabolism of drugs that each enzyme contributes to, is estimated by 
the relative size of each section of the corresponding chart. Those enzyme polymorphisms that have 
already been associated with changes in drug effects are separated from the corresponding pie charts. 
ADH, alcohol dehydrogenase; ALDH, aldehyde dehydrogenase; CYP, cytochrome P450; DPD, 
dihydropyrimidine dehydrogenase; NQO1, NADPH:quinone oxidoreductase or DT diaphorase; COMT, 
catechol O-methyltransferase; GST, glutathione S-transferase; HMT, histamine methyltransferase; NAT, N-
acetyltransferase; STs, sulfotransferases; TPMT, thiopurine methyltransferase; UGTs, uridine diphospho 
glucuronosyltransferases; taken from (Evans and Relling, 1999) with modifications. 
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Three quarters of the 200 most prescribed drugs in the USA in 2002 are getting 
metabolized before they leave the human body. Three quarters of those again are 
substrates of cytochrome P450 (CYP) enzymes and one eighth are substrates of uridine 
diphospho (UDP) glucuronosyltransferases (UGTs), the major enzymes of metabolism 
phase II (Williams et al., 2004). The huge majority of phase I enzymes are cytochrome 
P450s (CYPs) (Evans and Relling, 1999), external monooxygenases that catalyze the 
introduction of a single atom of molecular oxygen to a substrate while the other oxygen 
atom is reduced to water (Bernhardt, 2006). UGTs catalyze the transfer of a glucuronic 
acid moiety from UDP-α-D-glucuronic acid (UDP-GA) to their substrates (Mackenzie et al., 
2005). The fact that one in ten prescribed drugs is converted by an UGT enzyme before it 
leaves the human body (Williams et al., 2004) illustrates the enormous relevance of this 
class of enzymes for drug metabolism.  
In contrast, glucuronidation does not always lead to detoxification (Ritter, 2000). 
Pharmacologically active metabolites are described as well, as for example the 6-
glucuronide of morphine (van Dorp et al., 2008) or retinoyl β-glucuronide (Formelli et al., 
1996); hence, the usage of a glucuronide as active pharmaceutical ingredient (API) is 
cogitable. Further approaches study the applicability of glucuronides as prodrugs in 
cancer therapy, since a higher activity of β-glucuronidase (the UGT antagonist hydrolyzing 
the glycosidic bond of glucuronides) in cancer cells could release the cytotoxic drug in the 
tumor (Chen et al., 2003). In addition to those metabolites with direct pharmacological 
activity, the formation of chemically reactive glucuronides is also known (Ritter, 2000). 
Glucuronides that result from the addition of the glucuronic acid group to a carboxylic 
acid group of the substrate are referred to acyl glucuronides. They are of great 
pharmacological interest because of their special properties and risks. Besides their 
chemical instability caused by hydrolysis and acyl migration, acyl glucuronide metabolites 
are reactive electrophiles, which are discussed to have toxic properties due to their ability 
to bind covalently to proteins, which may lead to immunogenic products (Bailey and 
Dickinson, 2003; Regan et al., 2010) The subject of toxicity of acyl glucuronides is 
discussed controversial, with some scientists suggesting that the approval of new drugs 
that are known to be metabolized to acyl glucuronides should be called into question 
generally. On the other hand, knowledge about general acyl glucuronide toxicity is not 
sufficient enough to draw such rigorous conclusions; not least since there are many drugs 
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forming acyl glucuronides, as e.g. ibuprofen, which emerged to be safe (Adams, 1992; 
Boelsterli, 2011). Another mechanism of UGT caused toxicity brings toxic substances in 
form of glucuronides to their site of action, like N-hydroxy arylamines, released from their 
glucuronides by the acidic pH value in the bladder, are thought to be involved in the 
initiation of bladder cancer (Babu et al., 1995). There is a huge demand on the part of the 
pharmaceutical industry on purified glucuronide metabolites, since the occurrence of 
pharmacologically or chemically reactive glucuronides implicates their requirement for 
toxicity studies. A further market for purified glucuronides is founded by a recently 
published guidance for industry concerning the safety testing of drug metabolites from 
the Food and Drug Administration (FDA). It recommends that “metabolites identified 
only in human plasma or metabolites present at disproportionately higher levels in 
humans than in any of the animal test species should be considered for safety 
assessment. Human metabolites that can raise a safety concern are those formed at 
greater than 10 percent of parent drug systemic exposure at steady state” (US 
Department of Health and Human Services, 2008). In this document, a disproportionate 
drug metabolite is defined as “a metabolite present only in humans or present at higher 
plasma concentrations in humans than in the animals used in nonclinical studies.” The 
glucuronidation of amine groups leads to N-glucuronides. Their production is preferred by 
humans and higher primates, whereas this phenomenon is mainly restricted to the 
glucuronidation of tertiary amines (Chiu and Huskey, 1998). A hypothesis for an 
explanation of this occurrence concerns the UGT isoform which is mainly responsible for 
N-glucuronidation of tertiary amines; in humans this seems to be UGT1A4. Since the gene 
cluster for the UGT1 family is highly conserved, a mutation in the first exon of UGT1A4 may 
be responsible for the deficiency of some organisms to form charged quarternary N+-
glucuronides (Chiu and Huskey, 1998; Green and Tephly, 1998). Since there are many APIs 
nowadays on the market with a tertiary amine which is metabolized to a quarternary N+-
glucuronide (Green and Tephly, 1998), the issue of disproportionate UGT metabolites 
could be of severe importance for the pharmaceutical industry due to the required 
toxicity studies of the respective metabolites. As for active metabolites, purified 
glucuronides are needed. A further market for the production of pure glucuronides as 
fine chemicals is justified in the requirement as reference standards, e.g. in doping control 
(Saudan et al., 2006).   
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1.2 UGTs 
UTGs (EC 2.4.1.17, see Table 1) increase the hydrophilicity of their substrates by 
conjugating them with a glucuronic acid moiety deriving from UDP-GA and thereby 
facilitating their renal or biliary excretion (Mackenzie et al., 2005). Substrates can be 
different kinds of endogenous or exogenous compounds like bilirubin, steroids, bile acids 
or hormones and drugs, environmental toxicants or carcinogens (Tukey et al., 2000). 
They are expressed in the liver, gastrointestinal tract, esophagus, brain, kidney, olfactory 
epithelium, pancreas, mammary gland, prostate, lung and skin (Tukey et al., 2000). UGTs 
belong to the family of glycosyltransferases (GTs, EC 2.4, see Table 1), which catalyze the 
generation of a glycosidic bond using an activated sugar donor with a phosphate leaving 
group. Nucleotide sugar dependent GTs can be classified in two groups, GT-A or GT-B, 
according to their structural fold (Lairson et al., 2008). Further categorization can be 
done into an inverting or retaining reaction mechanism concerning the configuration of 
the bondage at the anomeric carbon of the sugar. Those result in four clans: GT-A and GT-
B inverting enzymes compose clan I and clan II and GT-A and GT-B inverting enzymes are 
clan III and clan IV. Human UGTs belong to the GT1 family; they are inverting enzymes that 
use UDP coupled sugars and show a GT-B structural fold which makes them members of 
Clan II (Lairson et al., 2008; Radominska-Pandya et al., 2010). Within the GT1 family, UGTs 
belong to the UDP glycosyltransferase superfamily (which is also abbreviated by UGT, EC 
2.4.1, see Table 1), which is based on a characteristic signature sequence and consists of 4 
families with totally 22 members in humans (Mackenzie et al., 1997; Mackenzie et al., 
2005). An overview of the EC number definitions is given in Table 1. 
 
Table 1: EC number derivation of UGTs.1 
EC number Definition 
2 Transferase 
2.4 Glycosyltransferase 
2.4.1 Hexosyltransferase 
2.4.1.17 Glucuronosyltransferase 
                                                        
1 http://www.chem.qmul.ac.uk/iubmb/enzyme/ 
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The 19 human members from UGT families 1 and 2 (subfamily A and B) prefer UDP-GA as 
sugar cofactor. Therefore they are named glucuronosyltransferases. The UGT3 family 
consists of two isoenzymes. While UGT3A1 catalyzes N-acetylglucosaminidations of 
endogenous and exogenous substrates (Mackenzie et al., 2008), UGT3A2 uses UDP-
glucose and UDP-xylose for the conjugation of endogenous and exogenous substrates. 
However, due to the low expression level in the main organs of human metabolism, liver 
and gastrointestinal tract, UGT3A2 is not supposed to play an important role for drug 
metabolism (Mackenzie et al., 2011). The UGT8 family just contains one human isoenzyme, 
which uses UDP-galactose to catalyze the synthesis of galactosylceramide (Bosio et al., 
1996). The transfer of a glycoside moiety seems to be an evolutionary conserved reaction, 
since UDP glycosyltransferase sequences can be found in mammals, fish, worm, virus, 
yeast, plants, bacteria, and insects (Mackenzie et al., 1997; Bock, 2003). 
 
1.2.1 UGT isoforms and gene arrangement 
There are two UGT families mainly acting as glucuronosyltransferases, UGT1 and UGT2, 
with UGT2 beeing splitted into two subfamilies UGT2A and UGT2B. The human UGT1 
family contains 13 genes with nine functional isoforms (UGT1A1, UGT1A3, UGT1A4, UGT1A5, 
UGT1A6, UGT1A7, UGT1A8, UGT1A9 and UGT1A10) and four pseudogenes (UGT1A2P, 
UGT1A11P, UGT1A12P and UGT1A13P). The genes for all isoforms are arranged in one gene 
on chromosome 2q37 and mRNAs are produced by alternative splicing. For each isoform, 
there is an individual promoter and first exon, which is spliced to common four further 
exons. So, all the 13 transcripts possess an individual N-terminal part and an identical C-
terminal part. With respect to sequence homologies of the polypeptides of the first 
exons, the genes could be clustered into four groups. UGT1A1 and UGT1A6 comprise an 
own group, respectively; their first exon polypeptides just have a sequence similarity of 
50 % to each other and also to the other groups. UGT1A2P – UGT1A5 and UGT1A7 – 
UGT1A13P comprise groups number three and four, respectively. The polypeptides of 
their first exons exhibit sequence homologies of 75 – 92 % within each group (see Figure 
2, (Mackenzie et al., 2005)).  
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Figure 2: The human UGT1 family. Each exon 1 is represented by a coloured rectangle and its position 
relative to exons 2-5 is indicated. Exons 2-5, which are joined to each first exon in the mature transcript, are 
shown in grey. Pseudogene names end in the label P. The exons are not drawn to scale. The human UGT1 
locus extends over approximately 200 kb. Exon clusters are indicated by different colours. The figure is 
derived from Build 35.1 of the human genome; taken from (Mackenzie et al., 2005) with modifications. 
 
The UGT2 family consists of subfamilies UGT2A and UGT2B. The UGT2A gene family 
comprises three functional isoforms (UGT2A1, UGT2A2 and UGT2A3). UGT2B is composed of 
12 isoforms with seven functional isoforms (UGT2B4, UGT2B7, UGT2B10, UGT2B11, UGT2B15, 
UGT2B17, UGT2B28) and five pseudogenes (UGT2B24P, UGTB25P, UGT2B26P, UGT2B27P, 
UGT2B29P). The genes for all UGT2 isoforms are located on chromosome 4q13. In contrast 
to the UGT1 family, there is no usage of common exons in family UGT2, with exeption of 
UGT2A1 and UGT2A2, which also just have an own first exon, respectively, and share exon 
2 – 6. Additionally, all genes of family UGT2 possess 6 exons, respectively (see Figure 3, 
(Mackenzie et al., 2005)).  
 
 
 
Figure 3: The human UGT2 family. Each gene, consisting of six exons, is represented by a coloured 
rectangle, except for that which is labeled “2A1/2”, which represents seven exons. The human UGT2A1 and 
UGT2A2 genes contain unique first exons (2A1 and 2A2) and a shared set of five downstream exons (exons 2-
6 in grey). Pseudogene names end in the label P. The genes are not drawn to scale. The human UGT2 genes 
extend over approximately 1.45 Mb. The figure is derived from Build 35.1 of the human genome; taken from 
(Mackenzie et al., 2005) with modifications. 
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1.2.2 Structure and intracellular organization of UGTs 
UGT proteins encompass two domains of approximately the same size; the more 
conserved C-terminal domain carries the UDP cofactor binding site and is - at least within 
the UGT1 family and for UGT2A1 and UGT2A2 - identical due to exon sharing. The 
individual N-terminal domain is responsible for substrate binding and, thus, for substrate 
specificity (Meech and Mackenzie, 1997; Bock and Kohle, 2009). UGTs consist of 
approximately 530 amino acids; approximately half of the protein is derived from exon 1 
and constitutes the N-terminal domain (Tukey and Strassburg, 2001). There is a 
characteristic signature sequence (Prosite accession number PS00375) in the C-terminal 
half, which can be found in all UDP glycosyltransferases and which is thought to be 
involved in the UDP sugar cofactor binding (Mackenzie et al., 1997). UGT enzymes are 
located in the endoplasmic reticulum (ER) membrane and the nuclear envelope. They 
contain a hydrophobic domain near the C-terminus, which anchors the protein in the 
membrane (Radominska-Pandya et al., 2005). The basic C-terminal part of the enzyme is 
located in the cytoplasm, the N-terminal part in the ER lumen. Most UGTs possess an N-
terminal signal peptide, which directs the protein to the ER during translation and is then 
cleaved off (Tukey and Strassburg, 2001; Radominska-Pandya et al., 2005). The UGT 
protein structure is schematically shown in Figure 4.  
 
 
Figure 4: Putative protein structure of UGT proteins. (a) Functional domains are depicted in a linearized 
protein. (b) The UGT protein as it is presumed to be located within the endoplasmic membrane is depicted. 
ER: endoplasmic reticulum; taken from (Nagar and Remmel, 2006). 
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The intraluminal localization of the active site of UGT enzymes requires transporters for 
the transfer of nucleotide sugars, which are needed as UGT cofactors, through the ER 
membrane. This is actualized by an antiporter that uses UDP-N-acetylglucosamine as 
counterpart (Bock and Kohle, 2009). Likewise, glucuronide transporters are required for 
the transport of UGT metabolites out of the ER (possibly organic anion transporters 
located in the ER membrane) and at the same time into the ER for hydrolysis by ER 
localized β-glucuronidase (Bock and Kohle, 2009). Multidrug resistance-associated 
proteins and organic anion transporters are involved in the transfer of glucuronides out 
of the cell (Ishii et al., 2010a). Several studies indicate that UGTs may act as oligomers; 
dimers are believed to be responsible for monoglucuronide formation, whereas 
tetramers are assumed to support diglucuronide formation, e.g. in the case of bilirubin 
(Bock and Kohle, 2009). The functions of UGTs may be further affected by 
phosphorylation (Basu et al., 2008), glycosylation (Barbier et al., 2000) and protein-
protein association with CYPs (Ishii et al., 2010b). 
 
1.2.3 Requirements for glucuronidation and UGT reaction mechanism 
For a glucuronidation reaction UGTs require a substrate with a functional group suitable 
for glucuronidation as well as the cofactor UDP-GA (or other nucleotide sugars). This 
cofactor is delivered by UDP glucose-6-dehydrogenase (UGDH, EC 1.1.1.22) in humans 
(Egger et al., 2010). This soluble enzyme catalyzes the dehydrogenation of UDP-α-D-
glucose (UDP-Glc) to UDP-GA, thereby protonating two nicotinamide adenine 
dinucleotide (NAD+) molecules (Sommer et al., 2004). UDP-Glc in turn is synthesized from 
the glycolysis intermediate glucose-1-phosphate and uridine triphosphate (UTP) under 
cleavage of pyrophosphate by UDP glucose pyrophosphorylase (UGP, EC 2.7.7.9) (Peng 
and Chang, 1993). UDP-GA has further important functions in the human body, since it is a 
precursor for the synthesis of extracellular matrix glycosaminoglycans (heparan sulfate, 
hyaluronan, and chondroitin sulfate) and UDP-xylose, the initial sugar in 
glycosaminoglycan synthesis on proteoglycans (Moriarity et al., 2002; Viola et al., 2008). 
UDP-Glc is a key intermediate in the carbohydrate metabolism and has versatile 
applications, e.g. for glycogen biosynthesis and protein and lipid glycosylation (directly 
and over a further conversion to UDP-galactose) (Lecca and Ceruti, 2008). The metabolic 
Introduction 
- 9 - 
pathway from glucose-1-phosphate to a glucuronide, with 4-methylumbelliferone as 
exemplary substrate, is given in Figure 5. 
 
 
Figure 5: Metabolic pathway from glucose-1-phosphate to a glucuronide in humans. The glycolysis product 
glucose-1-phosphate (1) is coupled to UTP to build UDP-Glc (2) with a simultaneous splitting off of 
pyrophosphate (PPi) by UGPase. (2) is then oxidized by UGDH to UDP-GA (3). After the transport of UDP-GA 
through the ER membrane, it is used by UGT as cofactor for glucuronidation, which releases UDP. 
Exemplarily, the glucuronidation of 4-methylumbelliferone (4) as substrate to 4-methylumbelliferyl-
glucuronide (5) is shown. 
 
The UGT reaction mechanism is supposed to proceed according to a SN2 reaction 
mechanism, since an inversion of the configuration at the anomeric carbon of the 
glucuronic acid moiety takes place. That means UDP-α-D-glucuronic acid is used for the 
production of an aglycon-β-D-glucuronide (Ouzzine et al., 2003). It is assumed that a 
nucleophilic group is activated at the substrate by deprotonation by a base. This 
nucleophile in turn may attack the anomeric carbon of the glucuronide moiety of UDP-GA, 
which would lead to the formation of the aglycon-β-D-glucuronide and the splitting-off of 
UDP, which is enabled by an interaction of Mg2+ with the pyrophosphate (Ouzzine et al., 
2003) (see Figure 6).  
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nitrothiophenol produced by guinea pig liver microsomes (Smith et al., 1992) and from 
malotilate, found in rat bile (Nakaoka et al., 1989), or from thiones like the S-glucuronides 
from HMR1098 found in rat, dog and human bile (Ethell et al., 2003) or from AR-
C133611XX, built by dog hepatocytes (Martin et al., 2003).  
Besides the use of UDP-GA as sugar cofactor for the conjugation of different 
substrates, UGTs have also been shown to be able to use other UDP-sugar cofactors like 
UDP-Glc, UDP-α-D-galactose (UDP-Gal) or UDP-α-D-xylose (Senafi et al., 1994; Mackenzie 
et al., 2003; Toide et al., 2004; Tang and Ma, 2005). This may also be pharmacologically 
relevant since glucoside metabolites have been reported to occur in humans (Tang, 1990; 
Paibir and Soine, 1997; Nakazawa et al., 2006). Tang and Ma showed that only one in two 
substrates is glucosidated or galactosidated in the presence of UDP-Glc or UDP-Gal, 
respectively, by human liver microsomes, even though both substrates are 
glucuronidated in the presence of UDP-GA (Tang and Ma, 2005). In a further study, eight 
human UGT isoforms (five from UGT1 family and three from UGT2B family) were 
investigated for their ability to glucosidate AS-3201. It was shown that three members 
from UGT1 and all from UGT2B family were able to glucosidate the substrate, whereas 4 
members from solely UGT1 family were able to glucuronidate it (Toide et al., 2004).  
 
1.3 Production of glucuronides 
Purified glucuronides are required in milligram amounts as analytical standards and in 
gram amounts for toxicity studies. Therefore, efficient chemical or biological glucuronide 
production systems are required. Those have been reviewed by the author of this work in 
a recent publication (Zöllner et al., 2010). A chemical method, on which many glycoside 
synthesis procedures including aryl and alkyl O-glucuronidations are based on, is the 
Koenigs-Knorr reaction (Stachulski and Jenkins, 1998; Wimmer et al., 2004). Using this 
reaction, many O-glucuronides could be produced successfully so far, e.g. those of 
phenols (Goenechea et al., 2001) or steroids (Thevis et al., 2001). Also, the production of 
acyl glucuronides like those of ibuprofen (Johnson et al., 2007) or diclofenac (Kenny et al., 
2004) or of N-glucuronides like the secondary N-glucuronide of 4-aminobiphenyl (Al-
Zoughool and Talaska, 2005), the tertiary N-glucuronides of norgallopamil and 
norverapamil (Mutlib and Nelson, 1990) or the charged quarternary N+-glucuronide of 4-
(2-methyl-1H-imidazol-1-yl)-2,2-diphenylbutanamide (Araya et al., 2007) could be achieved 
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by chemical synthesis. S-glucuronides are not impossible to synthesize chemically as well, 
as shown by the production of HMR1098-S-glucuronide methyl ester (Ethell et al., 2003). 
However, not all glucuronides can be produced by chemical methods; this is especially 
true for monoglucuronides of molecules with several functional groups that are potential 
sites of glucuronidation (Zöllner et al., 2010). To facilitate the production of these 
metabolites, many biological approaches have been developed. Since the activity of UGT 
enzymes is highly dependent on their membrane embedment, the purification and use of 
purified enzymes is difficult (Radominska-Pandya et al., 2005); nonetheless, reports on 
purifications of human UGTs can be found (Seppen et al., 1995; Kurkela et al., 2004). 
Widely used enzyme-dependent catalysis of glucuronidation is based on cell lysates or 
microsomes, which are available from cells natively containing UGTs, like liver cells, or 
from cells recombinantly expressing UGT enzymes (Zöllner et al., 2010). Interestingly, the 
UGT reaction side product UDP has been shown to inhibit the UGT reaction (Fujiwara et 
al., 2008). It has been speculated that the activity of purified enzymes is further 
decreased by this inhibitory effect of UDP, which is depleted in intact cells by luminal 
nucleoside diphosphatases. Since the activity of this enzyme in turn is calcium dependent 
and microsome incubation conditions in general do not contain calcium, even for 
microsomal incubations this might be relevant (Fujiwara et al., 2008). Microsomes from 
baculovirus infected insect cells, which overexpress UGT isoforms, are popular. They have 
excellent prerequisites for metabolite productions, since they lack endogenous UGT and 
CYP activities and subsequently, the risk of the production of undesired UGT or CYP 
metabolites due to background activities is low (Brandon et al., 2003). Those methods are 
capable of small scale metabolite production or metabolism studies in general, but for 
the production of larger amounts of glucuronide they are not practicable since they all 
require the addition of the very expensive cofactor UDP-GA. Background activities by 
other drug metabolizing enzymes (DMEs) or the lack of tissue specific UGT isoforms 
(UGT1A7, UGT1A8, UGT1A10, UGT2A1, and UGT2A2 are not expressed in human liver 
(Fisher et al., 2001; Sneitz et al., 2009)) can cause further complications when using 
microsomes or homogenates from a defined tissue or organism. The preparation of 
glucuronides from living animals, body fluids or plants also has been tried, but again, the 
up-scaling is very demanding (Zöllner et al., 2010). The problems of the expensive 
cofactor UDP-GA and up-scaling can be circumvented by whole-cell biotransformations. 
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This method uses complete cells expressing the biocatalyst and in case of UGTs, they may 
produce endogenously UDP-GA. It has been applied in different cells, like mammalian cell 
lines, but there are also the drawbacks of endogenous background DME activities and 
tissue dependent UGT isoforms (Zöllner et al., 2010). First results of a promising new 
technology, showing the suitability of recombinant fission yeast for the production of 
glucuronides using at least human UGT1A9, already existed at the beginning of this work. 
 
1.4 Fission yeast Schizosaccharomyces pombe as a biotechnological tool 
The biotechnological production of different kinds of products requires adequate host 
organisms. The fission yeast Schizosaccharomyces pombe was isolated from an East 
African millet beer in 1893 and was firstly described by Paul Lindner (Lindner, 1893). 
“Pombe” is the Swahili word for beer. S. pombe is a unicellular, eukaryotic, rod-shaped 
organism which belongs, as the baker’s yeast Saccharomyces cerevisiae, to the kingdom of 
fungi and the phylum of ascomycota. Fission yeast and baker’s yeast are the two most 
commonly used yeasts in molecular biology. In contrast to baker’s yeast, which 
reproduces by budding, fission yeast grows at the cell tips and divides by medial cleavage. 
Concerning the evolution, both yeasts are differing from each other as each of them from 
man; many proteins of fission yeast even seem to be more similar to higher eukaryotes 
than their homologues in baker’s yeast (Sipiczki, 2000). This is reflected in a number of 
cellular processes in S. pombe, which are more similar to those in higher eukaryotes than 
to S. cerevisiae, e.g. the signalosome, mRNA splicing, RNA interference, chromosome 
associated proteins or chromosome structure (Forsburg, 2005). In contrast, S. cerevisiae 
has a higher similarity to higher eukaryotes in other aspects, e.g. in the peroxisome 
(Forsburg, 2005). S. pombe is a suitable model organism for the study of molecular and 
cell biology processes of higher eukaryotes. It gained high profile since Paul Nurse 
(together with Lee Hartwell and Tim Hunt) received the Nobel Prize for Physiology or 
Medicine in 2001 for his studies on cell cycle regulation. In addition to its value for basic 
research, S. pombe possesses several properties that qualify it as an excellent tool for 
biotechnological purposes (Takegawa et al., 2009). Due to decades of basic research, 
many molecular biology tools and techniques have been developed for fission yeast (Siam 
et al., 2004; Forsburg and Rhind, 2006). The genome of S. pombe is completely sequenced 
(Wood et al., 2002) and it possesses the “generally regarded as safe” (GRAS) status 
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allowing a utilization in security level 1 laboratories and the comparatively easy 
production of substances which are intended to be applied on humans. Furthermore, 
DNA microarray, proteome and transcriptome data are available (Takegawa et al., 2009; 
Worner et al., 2009). For the expression of human mitochondrial or ER membrane 
proteins, S. pombe displays advantages to bacteria or baker’s yeast. It possesses 
eukaryotic subcellular structures in contrast to bacteria, and shows more human-like 
posttranslational modification patterns like protein folding or glycosylation (Chappell and 
Warren, 1989; Parodi, 1999; Takegawa et al., 2009). This in turn, together with correct 
protein folding, is difficult or impossible in prokaryotes. However, even better 
preconditions are given by use of cells from insects or mammalian cell lines, but long 
generation times and demanding cultivation conditions require alternative tools 
(Takegawa et al., 2009). In the past, S. pombe has been shown to be an excellent host for 
the functional expression of membrane bound DMEs like microsomal or mitochondrial 
CYPs (Bureik et al., 2002; Dragan et al., 2005; Peters et al., 2007). Using recombinant 
fission yeast cells, the production of the respective metabolites was successfully 
established using the technique of whole-cell biotransformation (Peters et al., 2007; 
Peters et al., 2009). Moreover, prior to this work, Călin-Aurel Drăgan already showed the 
functional expression of UGT1A9 in fission yeast. The lack of the essential UGT cofactor 
UDP-GA in fission yeast cells was compensated by the coexpression of human UGDH, 
which could be shown to efficiently deliver UDP-GA endogenously, and allowed a self 
sufficient glucuronide production in whole-cell biotransformations.  
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2 Aims and scopes  
The significant demand for purified glucuronides is illustrated by the above mentioned 
existence of biologically or chemically active metabolites, the recent FDA guideline on 
metabolite testing as well as the demand of reference standards including isotope-
labeled glucuronides. Toxicity studies require substance amounts of up to hundreds of 
grams of the purified metabolite. Chemical synthesis of glucuronides is not always 
possible, and the existing biological approaches suffer from three main disadvantages: (I) 
the dependency of UGT activity on phospholipids constrains the use of purified enzymes, 
(II) in vitro approaches always depend on the external addition of the expensive cofactor 
UDP-GA and (III) in vivo approaches suffer from difficult up scaling of the production in 
higher organisms and from restricted UGT expression or background activities in cell 
cultures. Fission yeast, being an eukaryotic organism, has a high potential to bypass the 
disadvantages of other biological systems. The functional expression of human UGT1A9 
and the glucuronide production in whole-cell biotransformations could successfully be 
accomplished prior to the beginning of this work. UDP-GA was provided intracellularly by 
the coexpression of human UGDH. Background activities by other UGTs were not 
expected since no UGT orthologous open reading frame could be found in fission yeast. 
The issue of up scaling should be easy to handle with fission yeast, since cultivation is far 
not as complex, expensive and risky in terms of contaminations as that of cell cultures. A 
first aim of this study was the application of the remaining 18 human UGT isoforms (and 
additionally the polymorphic variant UGT2B7*2) and rat UGT1A7 in this self-sufficient 
glucuronide production system. One recombinant fission yeast strain for each UGT should 
be established and tested for its ability to produce glucuronides in whole-cell 
biotransformations. The use of the cells in whole-cell biotransformations was especially 
important, since the “in-cell” production of UDP-GA and the possibility of easy up-scaling 
were to be confirmed. Besides the biotechnological utilization for the production of 
glucuronides, this system also appeared to be suitable to study molecular properties of 
single UGT isoforms like substrate or cofactor preferences. Since the usage of alternative 
sugar cofactors is known and fission yeast endogenously contains UDP-Glc and UDP-Gal, 
one interesting point was the question whether the fission yeast system is suited for the 
production of glycosides. If so, it could be used to investigate the ability of single UGT 
isoforms to catalyze those reactions. For this purpose, the coexpression of UGDH had to 
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be critically considered, since the endogenous UDP-Glc level may be decreased by the 
conversion to UDP-GA. Moreover, different types of glucuronides (with the glucuronide 
conjugated to different functional groups) display different properties in terms of charge 
or stability. A main difference between glucuronides and other glycosides (like glucosides 
or galactosides) is the charged acidic moiety occurring in glucuronides. Therefore, a focus 
was set on the applicability of this system on the production of the diverse kinds of 
glucuronide- and glycoside-metabolites.  
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ABSTRACT:
Drug metabolites generated by UDP glycosyltransferases (UGTs)
are needed for drug development and toxicity studies, especially in
the context of safety testing of metabolites during drug develop-
ment. Because chemical metabolite synthesis can be arduous,
various biological approaches have been developed; however, no
whole-cell biotransformation with recombinant microbes that ex-
press human UGTs was yet achieved. In this study we expressed
human UDP glucose-6-dehydrogenase together with several hu-
man or rat UGT isoforms in the fission yeast Schizosaccharomyces
pombe and generated strains that catalyze the whole-cell glucu-
ronidation of standard substrates. Moreover, we established two
methods to obtain stable isotope-labeled glucuronide metabolites:
the first uses a labeled aglycon, whereas the second uses 13C6-
glucose as a metabolic precursor of isotope-labeled UDP-glucu-
ronic acid and yields a 6-fold labeled glucuronide. The system
described here should lead to a significant facilitation in the pro-
duction of both labeled and unlabeled drug glucuronides for indus-
try and academia.
The metabolic steps that lead to drug clearance in the human body
are divided into two distinct parts, which encompass chemical mod-
ifications of the parent compound (phase I) and conjugations of parent
or phase I metabolites with endogenous molecules (phase II). As a
huge majority of the 200 most prescribed drugs in the United States
are metabolized in the human body (Williams et al., 2004), the
synthetic or biosynthetic accessibility of drug metabolites is a prereq-
uisite for drug development and toxicity studies. According to current
knowledge, cytochrome P450 (P450) systems are most important for
phase I (Bernhardt, 2005; Ingelman-Sundberg et al., 2007) and UDP
glycosyltransferases (UGTs) for phase II reactions (Mackenzie et al.,
2005), respectively. The human UGT superfamily consists of four
families with 22 isoenzymes: the 19 members of the UGT1 and UGT2
families (the latter encompassing subfamilies 2A and 2B) are primar-
ily involved in xenobiotic metabolism and efficiently use UDP glu-
curonic acid (UDP-GA) for the conjugation of drugs to glucuronic
acid (Mackenzie et al., 2005). UGT3A1 was recently shown to be a
UDP-N-acetylglucosaminyltransferase that also appears to have a
function in drug metabolism (Mackenzie et al., 2008); the catalytic
activity of UGT3A2 is not yet known; and UGT8A1 catalyzes the
transfer of galactose from UDP galactose to ceramide (Bosio et al.,
1996). Similar to many P450s, some drug-metabolizing UGT iso-
forms (e.g., UGT1A1, UGT1A6, UGT1A9, and UGT2B15) display
polymorphisms with a demonstrated association between genotype
and clinical pharmacokinetics (Katz et al., 2008). Many UGTs are
expressed in the liver, but other drug entry points such as epithelial
surfaces of the nasal mucosa, gut, skin, brain, prostate, uterus, breast,
placenta, and kidney also host UGT activity (Tukey and Strassburg,
2000). UGT enzymes are integrally associated with the membranes of
the endoplasmic reticulum, possibly with most of the protein oriented
toward the luminal side, and may form homo- and hetero-oligomeric
structures (Bock and Ko¨hle, 2009).
The formation of glucuronide metabolites may pose toxicological
problems to patients via increased drug activity on glucuronidation (Col-
ler et al., 2009) or cause dosage complications as a result of the uncon-
trolled rerelease of parent aglycones by systemic or enteric -glucuron-
idase activity (Prueksaritanont et al., 2006). In addition, acyl glucuronides
can exhibit chemical reactivity and can readily form covalently bound
adducts to proteins. Such protein adducts have been discussed as a cause
for idiosyncratic adverse drug reactions (Bailey and Dickinson, 2003).
The identification and structure elucidation of drug glucuronides can be
accomplished with milligram amounts, but safety testing may demand
gram quantities. Because classic chemical synthesis of glucuronide me-
tabolites can be cumbersome, various biological techniques have been
developed to this aim, which include metabolite isolation from animal
body fluids, the use of liver homogenates or liver microscale cultures, and
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enzyme preparations obtained after recombinant expression of metabo-
lizing enzymes in cell culture or microbial systems (Radominska-Pandya
et al., 2005; Khetani and Bhatia, 2008). However, each of these methods
has its specific drawbacks. For example, human liver microsomes contain
native UGTs, but their use may be hampered by their relative scarce
availability, batch-to-batch variations, and the absence of UGTs that are
only expressed in other tissues (Tukey and Strassburg, 2000; Jia and Liu,
2007). Heterologous expression of human UGTs in various mammalian
or insect cell lines was very helpful for the determination of basic kinetic
parameters of the enzymes, but it suffers from low expression levels, low
activity normalized to biomass, and stability problems (Radominska-
Pandya et al., 2005; Trubetskoy et al., 2008). Although functional UGT
expression in baker’s yeast has been shown per se, glucuronide produc-
tion could only be achieved after preparation of yeast microsomes and
addition of UDP-GA. The use of the costly cofactor UDP-GA at consid-
erable concentrations in existing preparative methods seems to be nec-
essary because of the endoplasmic membrane barrier, which limits the
entry of UDP-GA in the lumen. In addition, the use of microsomal
preparations implies the presence of many UGT isoforms and of other
systems that may reduce the yield of the desired glucuronide product by
cofactor competition.
Whole-cell biotransformations with recombinant microbes offer many
advantages with respect to scalable metabolite production, and corre-
sponding expression systems for human P450s have thus been estab-
lished in bacteria and yeasts (Ghisalba and Kittelmann, 2007; Pscheidt
and Glieder, 2008). In recent years, we showed the usefulness of recom-
binant strains of the fission yeast Schizosaccharomyces pombe that ex-
press human P450s for the production of P450 metabolites of illicit drugs
(Peters et al., 2009) and doping substances (Zo¨llner et al., in press).
Because no glucuronidation by whole-cell biotransformation with a uni-
cellular organism that recombinantly expresses human UGTs was yet
reported, it was the aim of this study to develop such a system using
S. pombe.
Materials and Methods
Fine Chemicals. 4-Methylumbelliferone (4MU), testosterone (T), and testos-
terone glucuronide (TG) potassium salt were purchased from Sigma-Aldrich
(Hamburg, Germany); 4-methylumbelliferone--D-glucuronide (4MUG) dihy-
drate was from Carl Roth (Karlsruhe, Germany); and 13C6-glucose was from
Euriso-Top (Saint-Aubin, France). Deuterated T was synthesized by Toroma
Organics Ltd. (Saarbru¨cken, Germany). All the other chemicals used were either
from Carl Roth or Sigma-Aldrich. Methanol [high-performance liquid chromatog-
raphy (HPLC) grade] was from Thermo Fisher Scientific (Waltham, MA).
Coding DNA Sequences. The cDNAs of human UGT1A1, UGT1A9,
UGT2A1, UDP glucose-6-dehydrogenase (UGDH), and/or rat UGT1A7 were
synthesized by Entelechon GmbH (Regensburg, Germany); cDNAs of human
UGT1A6, UGT1A7, UGT1A8, UGT1A10, UGT2B15, and UGT2B17 were syn-
thesized by GENEART GmbH (Regensburg, Germany).
Media and General Techniques. We used general DNA-manipulating meth-
ods, media, and genetic methods for fission yeast as described previously (Dra˘gan
et al., 2005). In addition, we used Edinburgh minimal medium (EMM) containing
100 g/l glucose for biotransformation assays and EMM containing 20 g/l 13C6-
glucose for the synthesis of isotope-labeled glucuronides.
Construction of Fission Yeast Strains. UGT cDNAs were cloned via NdeI
and BamHI into the integrative vector pCAD1 (Dra˘gan et al., 2005) that
integrates into the leu1 gene of the fission yeast genome, thereby compensating
an ura4 defect. UGDH cDNA was cloned into the expression vector pREP1
(Maundrell, 1993) using NdeI and BamHI yielding pREP1-UGDH. The cor-
rectness of all the constructs was verified by automatic sequencing (MWG-
Biotech, Ebersberg, Germany). The construction of fission yeast strains ex-
pressing functional UGTs was done in two steps. pCAD1-UGT constructs
were prepared, before transformation, as reported previously (Dra˘gan et al.,
2005), and used to transform yeast strain NCYC 2036 (hura4-D18). Trans-
formation was done, using competent cells prepared as described elsewhere
(Suga and Hatakeyama, 2005), and yielded strains CAD200, DB1, DB3, DB5,
DB23, DB24, DB25, DB26, DB32, and DB33. Correct integration into the
leu1 locus was verified by selection of leucine auxotrophs on EMM dishes
containing 5 M thiamine but no leucine. Subsequently, strains containing an
integrated UGT expression cassette were transformed with pREP1-UGDH as
described previously (Okazaki et al., 1990) to yield strains CAD203, DB11,
DB13, DB15, DB43, DB44, DB45, DB46, DB52, and DB53. Both fission
yeast expression vectors used in this study contain the strong endogenous nmt1
promoter (Maundrell, 1990, 1993) that permits expression regulation via the
presence or absence of thiamine in the medium. Therefore, transformed cells
were selected by plating on EMM dishes with 5 M thiamine to allow better
growth under repressed conditions. All the yeast strains used in this study are
available from PomBioTech GmbH (Saarbru¨cken, Germany).
Biomass Production. All the cultures were set up in absence of thiamine
to induce expression by the nmt1 promoter. Incubation was carried out at
30°C and 150 rpm. Ten milliliters of EMM containing the appropriate
supplements and lacking thiamine was inoculated with cells grown on a
dish for 3 days and incubated to stationary phase; these cells were then used
to inoculate 100 ml main cultures. Main cultures were incubated for 1 to 2
days for the parental strains NCYC2036, CAD200, DB1, DB3, DB5, DB23,
DB24, DB25, DB26, DB32, and DB33 and 2 to 5 days for the coexpressing
strains CAD203, DB11, DB13, DB15, DB43, DB44, DB45, DB46, DB52,
and DB53.
Whole-Cell Biotransformation Assay. The biomass was centrifuged
(3000g, 5 min, room temperature) and resuspended in 12 ml of EMM with 100
g/l glucose and supplements as required. Substrate was added to a final
concentration of 500 M by adding 600 l of 10 mM stock solutions in
ethanol. The biotransformations were carried out in 250-ml wide-neck Erlen-
meyer flasks for 72 h at 30°C and 150 rpm. Sample volumes of 2 ml were taken
at 0 and 72 h and centrifuged (10,000g, 5 min, room temperature). The cell
pellets were used to determine the biomass dry weight, whereas the superna-
tants were centrifuged again and then used for HPLC and liquid chromatog-
raphy/mass spectrometry (LC/MS) analyses. All the results shown were ob-
tained in at least three independent experiments.
Synthesis of Isotope-Labeled Glucuronide Metabolites. Because of the
high cost of the labeled compounds, these experiments were done at 1-ml
scale. For the comparison of the biosynthesis of labeled 4MUG with that of
unlabeled 4MUG, the cultivation of the cells was done in EMM containing
either 13C6-glucose or unlabeled glucose at a concentration of 20 g/l. Five
milliliters of medium without thiamine was inoculated with cells of strain
DB13 and incubated for 1 day at 30°C and 150 rpm. One milliliter of this
culture was then used to set up a 10-ml main culture, which in turn was
incubated for 3 days under the same conditions. The biomass was harvested
by centrifugation (3000g, 5 min, room temperature), and cells were resus-
pended in 1 ml of EMM containing a final concentration of 500 M 4MU
(50 l of an ethanolic 10 mM 4MU stock solution). The assay was carried
out in a 96-deep-well plate for 24 h at 30°C and 750 rpm in triplicate. For
the synthesis of stable isotope-labeled TG, the biotransformation assay was
carried out with strain DB53 as described before using T doubly deuterated
at C-2, deuterated in  and  positions at C-4 and C-6, respectively, and
deuterated at the C-17’s hydroxyl group as substrate. In the acidic fission
yeast medium, rapid exchange of the D atom in the OD group at C-17 leads
to the 4-fold labeled substrate. All the samples were prepared as described
above and analyzed by HPLC and LC/MS.
HPLC Analysis. HPLC was performed using a Series II 1090 system
(Hewlett Packard, Palo Alto, CA) equipped with a Lichrospher 100 column
(125  4.6 mm, RP-18, 5 M; Merck, Darmstadt, Germany) and a diode
array detector. The flow rate was 1 ml/min, and the column temperature
was 40°C. For the simultaneous detection of 4MU and 4MUG, the initial
mobile phase composition was 85% acetic acid (0.1%) (A) and 15%
methanol (B). B was linearly increased to 55% from 5 to 10 min, main-
tained at 55% for further 2 min, and then immediately returned to 15% until
the end of the run at 15 min. The eluents were monitored at 320 nm. The
retention times of 4MU and 4MUG were 12.4 and 8.4 min, respectively.
Quantification of 4MUG was done using an external 4MUG standard,
prepared in the initial mobile phase at a concentration of 200 M.
For the simultaneous detection of T and TG, the initial mobile phase
composition was 85% acetic acid (0.1%) (A) and 15% methanol (B). B was
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linearly increased to 90% from 2 min to 12 min and then immediately returned
to 15% B until the end of the run at 17 min. The eluents were monitored at 240
nm. The retention times of T and TG were 13.3 and 11.5 min, respectively. TG
concentrations were quantified using an external T standard at a concentration
of 200 M.
LC/MS. Samples were analyzed by nanospray ionization high-resolution
Fourier transform mass spectrometry (FTMS) in the positive ion mode using a
linear ion trap/Orbitrap hybrid mass spectrometer (Thermo Fisher Scientific)
equipped with a TriVersa NanoMate nanospray ion source (Advion, Ithaca,
NY). The instrument was coupled to the postcolumn flow of an Agilent
Technologies (Santa Clara, CA) 1100 HPLC detection system equipped with
a YMC ODS-AQ column (150  4 mm, 5 m; YMC America, Inc., Allen-
town, PA). The flow rate was 800 l/min, and the column temperature was
40°C. A linear gradient from 10 to 90% acetonitrile versus water containing 50
mM formic acid was applied from 0 to 14 min, maintained at 90% for further
3 min, and then immediately returned to the initial conditions for 3 min.
The bulk of the LC flow (700 l/min) was discarded, and approximately
100 l/min was passed to the nanospray source. The source voltage and
capillary voltage were set to 1.5 kV and 22 V, respectively. Nitrogen was
used as bath gas to slow down the motion of the ion population in the
C-trap. Collision-induced dissociation experiments (FTMSn) were per-
formed in the linear ion trap with collision energies of 26% normalized
collision energy at activation Q values of 0.250 with helium as collision
gas. The isolation width for collision-induced dissociation experiment in
the linear ion trap was set to 1 atomic mass unit. The FTMS mass
analyzer was operated at a resolution of approximately 60,000 full width at
half maximum at m/z 400 in the full-scan MS mode and approximately
15,000 full width at half maximum at m/z 400 in the full-scan MSn mode.
High-resolution mass spectra were acquired in the range of m/z 50 to 800.
Exact mass measurements in the FTMS- and FT-MSn mode were performed
after external calibration using the manufacturer’s calibration mixture from
previous LC/FTMSn investigations.
Results
Synthetic cDNA sequences coding for nine wild-type human UGTs or
rat UGT1A7, respectively, were each cloned into the integrative fission
yeast expression vector pCAD1 (Dra˘gan et al., 2005). Transformation of
fission yeast strain NCYC2036 with the resulting constructs yielded the
first set of strains, each of which expresses a single mammalian UGT
isoform (see Table 1; Fig. 1). The newly created strains grew normally
and did not display a visible phenotype (data not shown). As mentioned
above, UGT1 and UGT2 isoenzymes require UDP-GA as a cofactor,
which is synthesized from UDP glucose by UGDH in mammals. Al-
though the formation of UDP glucose in yeasts is known, wild-type
baker’s yeast does not produce UDP-GA (Oka and Jigami, 2006), and the
fission yeast genome contains no open reading frame that shows signif-
icant homology to mammalian UGDH enzymes (Wood et al., 2002).
Still, the presence of an endogenous UGDH activity as a result of a
nonhomologous fission yeast protein could not a priori be ruled out.
However, incubation of human UGT-expressing strains (Table 1) with
either 4MU (Uchaipichat et al., 2004) or T (Sten et al., 2009) as standard
substrate did not lead to detectable glucuronide formation (data not
shown). Therefore, for the development of a whole-cell biotransforma-
tion process, an endogenous source of UDP-GA had to be provided by
coexpression of UGDH (see Fig. 2). A synthetic cDNA coding for human
UGDH was cloned into the autosomally replicating expression vector
pREP1 (Maundrell, 1993) to yield the new plasmid pREP1-UGDH.
Transformation of all the UGT-expressing strains with this plasmid
yielded a new set of 10 UGT- and UGDH-coexpressing strains (Table 1;
Fig. 1). These new strains showed significantly reduced growth under
induced expression conditions and yielded biomass concentrations be-
tween 1 and 2 g/l after 2 to 5 days in contrast to biomass yields between
2 and 3 g/l for strains that only express UGTs (data not shown). Whole-
cell biotransformation assays showed that all the coexpressing strains
were able to catalyze the glucuronidation of either 4MU or T (Table 2).
The identity of the products 4MUG and TG was in each case confirmed
by LC/MS analysis (data not shown). As could be expected, the biotrans-
formation activities of the different UGT-expressing strains toward 4MU
varied from approximately 1 M/day for UGT1A1 and UGT1A6, re-
spectively, up to 150 M/day in the case of UGT1A9. In terms of specific
production rates (i.e., normalized to the biomass dry weight), the highest
values of almost 20 mol/day/g were achieved by the UGT1A9- and
UGT2A1-expressing strains, respectively, whereas the strains expressing
UGT1A1, UGT1A6, and rat UGT1A7, respectively, yielded only values
around or even less than 0.1 mol/day/g. Strain DB53 expressing human
UGT2B17 produced TG with a maximum space-time yield of 32.6
M/day and a maximum specific production rate of 3.1 mol/day/g. To
the best of our knowledge, these data show for the first time a successful
whole-cell biotransformation using recombinant human UGTs expressed
in a unicellular organism.
The availability of stable isotope-labeled glucuronides is a prereq-
uisite for the sensitive quantification of glucuronide metabolites in
biological matrices by LC/tandem MS, e.g., for the toxicokinetic
TABLE 1
Fission yeast strains used in this study
Expressed Protein(s) Species Type Strain Name Parent Strain Genotype Reference
NCYC2036 h ura4-D18 (Losson and Lacroute, 1983)
UGT1A1 Human DB1 NCYC2036 h ura4-D18 leu1::pCAD1-UGT1A1 This study
UGT1A6 Human DB23 NCYC2036 h ura4-D18 leu1::pCAD1-UGT1A6 This study
UGT1A7 Human DB24 NCYC2036 h ura4-D18 leu1::pCAD1-UGT1A7 This study
UGT1A8 Human DB25 NCYC2036 h ura4-D18 leu1::pCAD1-UGT1A8 This study
UGT1A9 Human CAD200 NCYC2036 h ura4-D18 leu1::pCAD1-UGT1A9 This study
UGT1A10 Human DB26 NCYC2036 h ura4-D18 leu1::pCAD1-UGT1A10 This study
UGT2A1 Human DB3 NCYC2036 h ura4-D18 leu1::pCAD1-UGT2A1 This study
UGT2B15 Human DB32 NCYC2036 h ura4-D18 leu1::pCAD1-UGT2B15 This study
UGT2B17 Human DB33 NCYC2036 h ura4-D18 leu1::pCAD1-UGT2B17 This study
rUGT1A7 Rat DB5 NCYC2036 h ura4-D18 leu1::pCAD1-rUGT1A7 This study
UGT1A1, UGDH Human DB11 DB1 h ura4-D18 leu1::pCAD1-UGT1A1/pREP1-UGDH This study
UGT1A6, UGDH Human DB43 DB23 h ura4-D18 leu1::pCAD1-UGT1A6/pREP1-UGDH This study
UGT1A7, UGDH Human DB44 DB24 h ura4-D18 leu1::pCAD1-UGT1A7/pREP1-UGDH This study
UGT1A8, UGDH Human DB45 DB25 h ura4-D18 leu1::pCAD1-UGT1A8/pREP1-UGDH This study
UGT1A9, UGDH Human CAD203 CAD200 h ura4-D18 leu1::pCAD1-UGT1A9/pREP1-UGDH This study
UGT1A10, UGDH Human DB46 DB26 h ura4-D18 leu1::pCAD1-UGT1A10/pREP1-UGDH This study
UGT2A1, UGDH Human DB13 DB3 h ura4-D18 leu1::pCAD1-UGT2A1/pREP1-UGDH This study
UGT2B15, UGDH Human DB52 DB32 h ura4-D18 leu1::pCAD1-UGT2B15/pREP1-UGDH This study
UGT2B17, UGDH Human DB53 DB33 h ura4-D18 leu1::pCAD1-UGT2B17/pREP1-UGDH This study
rUGT1A7, UGDH Rat, human DB15 DB5 h ura4-D18 leu1::pCAD1-rUGT1A7/pREP1-UGDH This study
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monitoring of glucuronides during nonclinical safety studies. There-
fore, having established a functional in vivo system for the production
of glucuronides, we investigated the possibility to produce isotope-
labeled glucuronide metabolites by applying two different strategies.
First, either nonlabeled T or 4-fold deuterated T (D4-T) were sub-
jected to whole-cell biotransformation with strain DB53 that coex-
presses UGT2B17 and UGDH (Fig. 3a). The comparison of the
LC/MS analysis of the extracted ion currents (EICs) of nonlabeled and
4-fold labeled TG, as well as the respective fragmentation spectra,
unambiguously shows the successful formation of D4-TG (Fig. 3,
FIG. 1. Fission yeast strain construction scheme. The procedure is exemplarily shown for UGT1A1. The uracil-deficient parental strain NCYC2036 was transformed using
the integrative plasmid pCAD1-UGT1A1. The resulting leucine-deficient strain DB1 was in turn transformed with the autosomal plasmid pREP1-UGDH yielding strain
DB11. For all the other UGT isoforms, the cloning procedure was done accordingly.
FIG. 2. Schematic representation of the engineered glucuronide biosynthetic pathway in recombinant fission yeast strains. The scheme shows in black the endogenous
pathway that leads to the formation of UDP glucose with branching points to several pathways of the central carbon metabolism; reactions depicted in blue indicate the
reaction steps introduced into the host by the heterologous coexpression of human UGDH and a mammalian UGT. Glucose (1) enters the cell and is converted to glucose
6-phosphate (2) by hexokinase (HK), which can be interconverted to glucose-1-phosphate (3) by phosphoglucomutase (PGM). The latter is conjugated with UDP by UDP
glucose pyrophosphorylase (UGPase) to yield UDP glucose (4). Human UGDH oxidizes 4 to UDP-GA (5), which then enters the lumen of the endoplasmic reticulum.
Eventually, the heterologously expressed mammalian UGT performs the conjugation of 5 to an aglycon (R) that passes both plasma and endoplasmic membrane to yield
a glucuronide metabolite (6). The glucuronide metabolite in turn leaves both the endoplasmic reticulum and the cell.
TABLE 2
Glucuronide metabolite formation rates determined in whole-cell biotransformations of fission yeast strains coexpressing human UGDH and mammalian
UGT enzymes
Strain Expressed Protein(s) Substrate Product
Space-Time Yield Specific Production Rate
Min Max Min Max
M/day M/day mol/day/g biomass dry wt. mol/day/g biomass dry wt.
DB11 UGT1A1, UGDH 4MU 4MUG 0.5 1.8 0.04 0.14
DB43 UGT1A6, UGDH 4MU 4MUG 0.6 3.5 0.04 0.22
DB44 UGT1A7, UGDH 4MU 4MUG 8.2 18.2 0.85 2.10
DB45 UGT1A8, UGDH 4MU 4MUG 5.9 23.0 0.43 2.50
CAD203 UGT1A9, UGDH 4MU 4MUG 64.2 151.5 12.10 19.70
DB46 UGT1A10, UGDH 4MU 4MUG 7.0 18.2 0.56 1.50
DB13 UGT2A1, UGDH 4MU 4MUG 22.8 114.5 4.00 19.50
DB52 UGT2B15, UGDH 4MU 4MUG 3.3 7.9 0.24 0.63
DB53 UGT2B17, UGDH 4MU 4MUG 0.0 0.0 0.00 0.00
DB53 UGT2B17, UGDH T TG 15.5 32.6 1.20 3.10
DB15 rUGT1A7, UGDH 4MU 4MUG 2.3 2.3 0.16 0.19
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b–e). Second, we intended to show a more general labeling technique
by using 13C isotope-labeled glucuronic acid as substrate and strain
DB13 (expressing UGT2A1 and UGDH). Based on the biosynthesis
scheme outlined above (Fig. 2), which leads to the endogenous
formation of UDP-GA in UGDH-expressing fission yeast strains, we
used 13C6-glucose as metabolic precursor of 6-fold labeled UDP-GA
(Fig. 3f). For this purpose, 13C6-glucose was added throughout all the
culturing periods before performing the biotransformation to deplete
FIG. 3. Production of stable isotope-labeled glucuronides using either a labeled aglycon (a–e) or a labeled sugar moiety (f–j). Scheme of the glucuronidation of
D4-testosterone (D4-T) by UGT2B17 (a). Comparison of the LC/MS analysis of the EIC of nonlabeled (b) and 4-fold labeled (d) TG and fragmentation spectra of TG
(TG 3 T, m/ztheo  289.21621,   0.28 ppm; c) and D4-testosterone glucuronide (D4-TG 3 D4-T, m/ztheo  293.24131,   0.17 ppm; e). Scheme of the
glucuronidation of 4MU by UGT2A1 with UDP-13C6-GA (f), which is produced from 13C6-glucose according to Fig. 2. Comparison of the LC/MS analysis of nonlabeled
(g) and 6-fold labeled (i) 4MUG and fragmentation spectra of 4MUG (4MUG3 4MU, m/ztheo  177.05462,   1.35 ppm; h) and 4MU 13C6-glucuronide (4MU-13C6G3
4MU, m/ztheo  177.05462,   0.57 ppm; j).
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12C-compounds in the central carbon metabolism of the cells as much
as possible. Again, the comparison of the LC/MS analysis of the EICs
of 4MUG and 4MU-13C6G proves the successful formation of the
6-fold labeled product (Fig. 3, g and i). In this case, the main signal
of the fragmentation spectra is not changed as it corresponds to the
unlabeled aglycon (Fig. 3, h and j). These results show that the
generation of isotope-labeled glucuronide metabolites can be conve-
niently achieved in vivo using the fission yeast system presented in
this study, and that according to requirements, either the aglycon or
the sugar moiety may be labeled.
Discussion
In this study, 10 fission yeast strains were cloned that express
either one of nine human UGTs or rat UGT1A7, respectively
(Table 1). As fission yeast does not have an endogenous UGDH
enzyme (Wood et al., 2002), neither of these strains displayed
glucuronidation activity toward 4MU or T because of a lack of
UDP-GA (data not shown). Therefore, a second set of strains was
created that coexpress the UGTs mentioned above together with
human UGDH. In addition to the intracellular production of
UDP-GA as such, its subcellular localization also had to be con-
sidered: in human cells, UDP-GA is formed by UGDH in the
cytoplasm and subsequently transported by nucleotide sugar trans-
porters into the lumen of the endoplasmic reticulum, where the
UGTs are located (Kobayashi et al., 2006). If after expression in
fission yeast the subcellular localization of both UGTs and UGDH
corresponds to their targeting in mammalian cells, then for bio-
transformation to occur at least one of the endogenous nucleotide
sugar transporters (such as vrg4 or hut1) (Nakanishi et al., 2001)
must be able to transport UDP-GA into the endoplasmic reticulum
lumen. This seems to be the case, because all the coexpressing
strains were able to catalyze the glucuronidation of either 4MU or
T (Table 2). The time-space yield of the different UGT-expressing
strains toward 4MU varied by roughly 2 orders of magnitude, from
approximately 1 M/day up to 150 M/day. With respect to the
relative activity of some of the UGT isoforms (e.g., UGT1A6
versus UGT1A9), these results partially vary from earlier results
obtained with enzymes purified from transfected human embryonic
kidney cells (Uchaipichat et al., 2004). However, the very different
experimental settings are likely to account for some of these
variations. Strain DB53 expressing human UGT2B17 produced TG
with a maximum space-time yield of 32.6 M/day and a maximum
specific production rate of 3.1 mol/day/g. Thus, a successful
whole-cell biotransformation using recombinant human UGTs ex-
pressed in a unicellular organism could be established for the first
time. Compared with the alternatives mentioned previously, a
significant benefit of this system is its self-sufficiency with respect
to the expensive cofactor UDP-GA. A further advantage is its
cost-effective scalability as a result of the endogenous generation
of all the reaction constituents except for the substrate. Although
fission yeast is at present not a widely used organism in biotech-
nology, its widely tolerable pH range makes adaptation to substrate
and product requirements easily achievable; for example, the pro-
duction of (notoriously unstable) acyl glucuronides may be done
under acidic conditions to avoid rapid degradation (Ebner et al.,
1999). In addition to up-scaling, scaling down could lead to a
simple and efficient high-throughput screening method for large-
scale UGT profiling or inhibition studies using living cells.
Because the availability of stable isotope-labeled glucuronides is
desirable for the LC/tandem MS analysis of glucuronide metabo-
lites in biological matrices, we established two different methods
for their preparation. In the first approach, a labeled aglycon served
as a substrate, as in a recent study where pooled human liver
microsomes were used for a similar biotransformation (Turfus et
al., 2009). In this case, 4-fold deuterated T was successfully
glucuronidated by strain DB53 (Fig. 3, a– e). Although this ap-
proach for the production of stable isotope-labeled glucuronides is
very straightforward, it depends on the availability of a sufficiently
labeled aglycon, which may not always be at hand. Moreover, in
some instances, unfavorable isotope effects may occur. Therefore,
a second strategy was developed that uses 13C6-glucose as a
metabolic precursor, which is converted within the UGDH-
expressing fission yeast strains to 13C6-labeled UDP-GA (Fig. 2).
Exemplarily, strain DB13 (expressing UGT2A1 and UGDH) was
successfully used for the production of 6-fold labeled 4MUG
(4MU-13C6G) by this method (Fig. 3, f–j). In conclusion, in this
study we show the functional expression of human UGDH with
nine human and one rat UGT enzymes in fission yeast that can be
conveniently used for the synthesis of either labeled or unlabeled
glucuronide metabolites by whole-cell biotransformation.
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ABSTRACT:
UDP-glycosyltransferases (UGTs) are an important group of enzymes
that participate in phase II metabolism of xenobiotics and use the
cofactor UDP-glucuronic acid for the production of glucuronides.
When acting on molecules bearing a carboxylic acid they can form
acyl glucuronides, a group of metabolites that has gained significant
interest in recent years because of concerns about their potential role
in drug toxicity. In contrast, reports about the production of drug acyl
glucosides (which might also display high reactivity) have been
scarce. In this study, we discovered the formation of acyl glycoside
metabolites of R- and S-ibuprofen (Ibu) by human liver microsomes
supplied with the cofactor UDP-glucose. Subsequently, human
UGT2B7*1 and UGT2B7*2 recombinantly expressed in fission yeast
Schizosaccharomyces pombe could be shown to catalyze these re-
actions. Moreover, we could enhance the glucoside production rate
in fission yeast by overexpressing the fission yeast gene
SPCC1322.04, a potential UDP-glucose pyrophosphorylase (UGPase),
but not by overexpression of SPCC794.10, and therefore suggest to
name this gene fyu1 for fission yeast UGPase1. It was interesting to
note that pronounced differences between the two polymorphic
UGT2B7 variants were observed with respect to acyl glucoside pro-
duction. Finally, using the metabolic precursor [13C6]glucose, we
demonstrated the production of stable isotope-labeled reference
standards of Ibu acyl glucoside and Ibu acyl glucuronide by whole-
cell biotransformation in fission yeast.
Introduction
The UDP-glycosyltransferases (UGTs) are a superfamily of en-
zymes that catalyze the addition of glycosyl residues to small
molecular-weight lipophilic chemicals and in this way play an
important role in the elimination of different endogenous and
exogenous compounds from the human body (Mackenzie et al.,
2005). Humans have 22 UGTs that belong to four families: UGT1,
UGT2 (with the subfamilies 2A and 2B), UGT3, and UGT8. The
19 human UGT isoforms in the UGT1 and UGT2 families have an
often overlapping but sometimes very distinct substrate selectivity
and are thought to typically prefer UDP-glucuronic acid (UDP-
GA) as a sugar donor. UGTs may convert carboxylic-acid-
containing drugs into acyl glucuronides (AGs), which because of
their special properties and risks are of considerable pharmacolog-
ical interest. It was noted decades ago that AGs are potentially
reactive electrophiles that can interact with and covalently bind to
nucleophilic targets (Faed, 1984). Accordingly, it was suggested
that glucuronidation is not always a harmless detoxication reaction
but that in some instances it can be a bioactivation pathway leading
to potential toxicity (Spahn-Langguth and Benet, 1992). However,
the overall toxicological significance of AGs is still a subject of
debate (Boelsterli, 2011; Stachulski, 2011).
The nonsteroidal anti-inflammatory drug ibuprofen (Ibu) acts as an
cyclooxygenase inhibitor and is predominantly orally applied as a
racemic mixture; in the body, much of the R-enantiomer is converted
to the active S-form (Lee et al., 1985). Ibu metabolism comprises a
complex interaction of different phase I and phase II enzymes includ-
ing several cytochrome P450 enzymes, dehydrogenases, and UGTs
(Adams, 1992; Spraul et al., 1993; Kepp et al., 1997; McGinnity et al.,
2000; Hao et al., 2005; Chang et al., 2008). To the best of our
knowledge, all UGT metabolites of Ibu described so far are glucu-
ronides, with the glucuronic acid being either attached to the acyl
moiety of the parent compound (yielding Ibu AGs) or to hydroxy
groups newly created in phase I metabolism.
In this study, we describe new acyl glycoside metabolites of Ibu. In
vitro studies with human liver microsomes (HLMs) and the substrates
(R)-()-ibuprofen (R-Ibu), (S)-()-ibuprofen (S-Ibu), and racemic
ibuprofen (rac-Ibu) demonstrated that such metabolites are only pro-
duced in the presence of the cofactor UDP-glucose (UDP-Glc), but
not UDP-galactose (UDP-Gal), thus confirming their identity to be
either the R- or S-enantiomers of Ibu acyl glucoside (Ibu-Glc).
UGT2B7 is one of the most important human UGT isoforms with
respect to drug clearance in general (Williams et al., 2004) and
significantly contributes to Ibu metabolism (Sakaguchi et al., 2004;
Kuehl et al., 2005). There are two important polymorphic variants of
this enzyme, UGT2B7*1 (268His) and UGT2B7*2 (268Tyr), with an
allelic distribution of approximately 1:1 in white persons and 3:1 in
Japanese individuals (Bhasker et al., 2000). Several studies demon-
strated notable differences in the catalytic activity of these two forms,
although this effect seems to be limited to certain substrates (Bernard
et al., 2006; Thibaudeau et al., 2006; Belanger et al., 2009). Like some
other UGT isoforms, UGT2B7 has been shown to use other UDP-
Article, publication date, and citation information can be found at
http://dmd.aspetjournals.org.
doi:10.1124/dmd.111.041640.
ABBREVIATIONS: UGT, UDP-glycosyltransferase; AG, acyl glucuronide; fyu1, fission yeast UDP-glucose pyrophosphorylase 1; HLMs, human liver micro-
somes; Ibu, ibuprofen; R-Ibu, (R)-()-ibuprofen; S-Ibu, (S)-()-ibuprofen; rac-Ibu, racemic ibuprofen; Ibu-AG, ibuprofen acyl glucuronide; Ibu-Glc, ibuprofen acyl
glucoside; UDP-GA, UDP--D-glucuronic acid; UDP-Gal, UDP--D-galactose; UDP-Glc, UDP--D-glucose; UGDH, UDP-glucose-6-dehydrogenase; UGPase,
UDP-glucose pyrophosphorylase; LC-MS, liquid chromatography-mass spectrometry; DAD, diode array detector; EMM, Edinburgh minimal medium.
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sugars in addition to UDP-GA, such as UDP-Glc and UDP-Gal, and
at least in some cases this property also seems to be substrate depen-
dent (Mackenzie et al., 2003; Tang et al., 2003; Tang and Ma, 2005).
We therefore investigated the ability of recombinantly expressed
UGT2B7*1 and UGT2B7*2 to produce Ibu-Glc using our previously
described fission yeast system (Dragan et al., 2010). Whole-cell
biotransformations with UGT2B7-expressing fission yeasts demon-
strated that the rate of metabolization of Ibu to Ibu-Glc depends on the
Ibu enantiomer and the enzyme variant. Moreover, overexpression of
an endogenous UDP-glucose pyrophosphorylase (UGPase) signifi-
cantly enhanced Ibu-Glc production by UGT2B7*1, but not by
UGT2B7*2, thus indicating a differential effect of cofactor availabil-
ity. We suggest to name this UGPase, which is described in this study
for the first time, fyu1, for fission yeast UGPase 1.
Materials and Methods
Chemicals. R-Ibu was purchased from Enzo Life Sciences, Inc. (Farm-
ingdale, NY), S-Ibu was purchased from Thermo Fisher Scientific (Waltham,
MA), and rac-Ibu disodium salt was purchased from Sigma-Aldrich (St. Louis,
MO). UDP-GA trisodium salt was purchased from Sigma-Aldrich, UDP-Glc
disodium salt was purchased from Merck (Darmstadt, Germany), and UDP-
Gal disodium salt was purchased from VWR (West Chester, PA).
[13C6]glucose was purchased from Euriso-Top (Saint-Aubin, France). Metha-
nol (high-performance liquid chromatography grade) was purchased from
VWR. All other chemicals used were either from Carl Roth (Karlsruhe,
Germany) or Sigma-Aldrich.
In Vitro Metabolism of Ibu Using HLMs. Pooled HLMs (BD Biosci-
ences, San Jose, CA) were incubated using UDP-GA, UDP-Glc, or UDP-Gal
as cofactor as indicated. In addition, incubations without a UDP-sugar cofactor
were done as a negative control. The total reaction volume was 100 l. Final
concentrations of in vitro incubations were 0.5 mg  ml1 protein, 50 mM Tris
HCl pH 7.5, 10 mM MgCl2, and 200 M ibuprofen (S-Ibu, R-Ibu, or rac-Ibu).
Reactions were started by the addition of 2 mM UDP-GA, UDP-Glc, or
UDP-Gal, and samples were incubated for 18 h at 37°C and then mixed with
an equal volume of acetonitrile. All experiments were done in triplicate.
Coding DNA Sequences. The cDNA for human UGT2B7*2 optimized for
expression in S. pombe was synthesized by Entelechon GmbH (Regensburg,
Germany). The cDNA of human UGT2B7*1 was generated by site-directed
mutagenesis using UGT2B7*2 as a template. The cDNAs of SPCC794.10 and
SPCC1322.04 (fyu1) were amplified by polymerase chain reaction using cells
of the S. pombe strain NCYC2036 (Losson and Lacroute, 1983) as a template.
For amplification and introduction of 5-NdeI- and 3-BamHI sites, the fol-
lowing oligonucleotides were used: SPCC794.10, 5-TAG TTT CAT ATG
TTG CAT CGT CGA ATT C-3 and 5-TTT GGA TCC TCA ACA CTC CAT
TAT TTT AC-3; and SPCC1322.04, 5-TAG ATA CAT ATG GAT TTG
GCA CC-3 and 5-TTG GAT CCT TAG TGC TCC AAG ATA TTG-3.
Media and General Techniques. General DNA manipulating methods as
well as media and genetic methods for fission yeast have been described
(Sambrook and Rusell, 2001; Forsburg and Rhind, 2006). In addition, Edin-
burgh minimal medium (EMM) containing 100 g  l1 glucose was used for
biotransformation assays and EMM with 20 g  l1 [13C6]glucose was used for
the synthesis of isotope-labeled glucuronides.
Construction of Fission Yeast Strains. Fission yeast strain construction
was in principle done as described previously (Dragan et al., 2010).
UGT2B7*1 and UGT2B7*2 cDNAs were cloned via NdeI and BamHI into the
integrative vector pCAD1 (Dragan et al., 2005), which disrupts the leu1 locus
of S. pombe and contains an ura4 marker gene. The construction of the uridine
diphospho-glucose-6-dehydrogenase (UGDH) expression plasmid pREP1-
UGDH has been described previously (Dragan et al., 2005). UGT2B7*1,
UGT2B7*2, SPCC794.10, and SPCC1322.04 ( fyu1) cDNAs were cloned
into the autosomal expression vector pREP1 using NdeI and BamHI, respec-
tively. The correctness of all constructs was verified by automatic sequencing
(Eurofins MWG Operon, Huntsville, AL or Seq-it GmbH, Kaiserslautern,
Germany). pCAD1 and pREP1 contain the strong endogenous nmt1 promoter
that permits regulation of expression via the presence or absence of thiamine
in the media. Therefore, transformed cells were grown on EMM dishes with 5
M thiamine to allow for better growth under repressed conditions.
All strains used in this study are listed in Table 1. Plasmids pCAD1-
UGT2B7*1 and pCAD1-UGT2B7*2 were prepared as described previously
(Dragan et al., 2005) and used for the transformation of the parental S. pombe
strain NCYC2036 (Losson and Lacroute, 1983) to yield strains DB7 and DB4.
Correct integration into the leu1 locus was verified by testing growth of clones
on EMM dishes without leucine. Subsequently, strains containing an integrated
UGT expression cassette were each transformed with pREP1-UGDH, pREP1-
SPCC794.10, and pREP1-SPCC1322.04, respectively, to yield strains DB14,
DB64, and DB65 from the parental strain DB4, and DB17, DB66, and DB67
from the parental strain, DB7, respectively. In addition, strains containing two
expression cassettes for UGT2B7*1 or UGT2B7*2 were generated by trans-
forming DB4 with pREP1-UGT2B7*2 and DB7 with pREP1-UGT2B7*1 to
yield strains DB62 and DB63, respectively.
Biomass Production. All liquid cultures lacked thiamine to induce expres-
sion by the nmt1 promoter. Incubations were performed at 30°C and 150 rpm.
Ten milliliters of EMM precultures containing the appropriate supplements
were inoculated with cells grown on a dish for 2 to 3 days and incubated to
stationary phase; these cells were then used to inoculate 100-ml main cultures.
Main cultures were incubated for 1 day for the strain NCYC2036; for 2 days
for the strains DB4, DB7, DB62, DB63, DB64, DB65, DB66, and DB67; and
for 5 days for the strains DB14 and DB17.
Whole-Cell Biotransformation Assay. Whole-cell biotransformation as-
says were done as described previously (Dragan et al., 2010) using S-Ibu,
R-Ibu, or rac-Ibu as substrate (from a 10 mM stock solution in 50% ethanol)
with a final concentration of 500 M. Afterward, culture samples were frozen
until sample preparation and liquid chromatography-mass spectrometry (LC-
MS) analysis. All experiments were done in triplicate.
Synthesis of Isotope-Labeled Glucuronide Metabolites. For the syn-
thesis of 13C6-labeled glucuronides, whole-cell biotransformation assays
were done in 200-l scale. A main culture (1.6 ml) was centrifuged (5 min,
3000g, and room temperature), washed with 1 ml of water to remove a
maximum of remaining unlabeled glucose, and resuspended in EMM
containing 20 g  l1 [13C6]glucose at 200 l. Ten microliters of a 10 mM
substrate stock solution (in 50% ethanol) were added to reach a substrate
concentration of 500 M. Samples were horizontally shaken in a 2-ml
reaction tube with a pinhole for 72 h at 30°C and 150 rpm. The biomass dry
weight was determined from the initial main culture. All experiments were
done in triplicate.
TABLE 1
Fission yeast strains used in this study
Strain Parental Strain Expressed Protein(s) Genotype Reference
NCYC2036 h ura4-D18 (Losson and Lacroute, 1983)
DB4 NCYC2036 UGT2B7*2 h ura4-D18 leu1::pCAD1-UGT2B7*2 This study
DB7 NCYC2036 UGT2B7*1 h ura4-D18 leu1::pCAD1-UGT2B7*1 This study
DB14 DB4 UGT2B7*2, UGDH h ura4-D18 leu1::pCAD1-UGT2B7*2/pREP1-UGDH This study
DB17 DB7 UGT2B7*1, UGDH h ura4-D18 leu1::pCAD1-UGT2B7*1/pREP1-UGDH This study
DB62 DB4 UGT2B7*2 h ura4-D18 leu1::pCAD1-UGT2B7*2/pREP1-UGT2B7*2 This study
DB63 DB7 UGT2B7*1 h ura4-D18 leu1::pCAD1-UGT2B7*1/pREP1-UGT2B7*1 This study
DB64 DB4 UGT2B7*2, SPCC794.10 h ura4-D18 leu1::pCAD1-UGT2B7*2/pREP1- SPCC794.10 This study
DB65 DB4 UGT2B7*2, SPCC1322.04 h ura4-D18 leu1::pCAD1-UGT2B7*2/pREP1- SPCC1322.04 This study
DB66 DB7 UGT2B7*1, SPCC794.10 h ura4-D18 leu1::pCAD1-UGT2B7*1/pREP1- SPCC794.10 This study
DB67 DB7 UGT2B7*1, SPCC1322.04 h ura4-D18 leu1::pCAD1-UGT2B7*1/pREP1- SPCC1322.04 This study
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Sample Preparation. Cell suspensions from whole-cell biotransformations
were thawed if frozen and diluted 1:1 with acetonitrile. All samples (from in
vitro incubations and whole-cell biotransformations) were centrifuged (5 min,
15,000g, and room temperature), the supernatant was centrifuged again (10
min, 15,000g, and room temperature), and the resulting supernatants were
analyzed by LC-MS.
Liquid Chromatography-Mass Spectrometry. Samples were analyzed on
an Agilent/HP 1100 series high-performance liquid chromatograph equipped
with a G1315B diode array detector (DAD) and a G1946A single quadrupole
mass spectrometer (Agilent Technologies, Santa Clara, CA). Components were
separated on a Lichrospher RP 18 column (particle size 5 m, column inner
diameter 4 mm, and length 125 mm; WICOM, Heppenheim, Germany) using
water (mobile phase A) and methanol containing 0.1% formic acid (mobile
phase B). The flow rate was 0.8 ml/min, and the column temperature was
40°C. LC-MS settings were as follows: flow profile 0 to 5 min, 10% B; 5 to
20 min, 10 to 90% B; 20 to 25 min, 90% B; 25 to 30 min, 10% B; run time
30 min; injection volume 10 l; detector 1 G1315B DAD; DAD range 200 to
600 nm, slit width 2 nm; detector 2 G1946A mass selective detector, ionization
electrospray ionization (), and mode scan; and N2 flow rate 12 l  min1,
nebulizer pressure 45 psig (0.07 bar), nebulizer temperature 350°C, capillary
voltage 3500 V, and fragmentor voltage 50 V. The quantification of metabo-
lites was done using an external S-Ibu straight calibration line prepared in a 1:1
mixture of mobile-phase components (concentrations from 10 to 250 M
S-Ibu). Labeled metabolites were quantified using an external S-Ibu standard of
100 M prepared in a 1:1 mixture of mobile-phase components.
Results
Human Liver Microsomes Produce Ibuprofen Acyl Glucosides
but Not Galactosides. HLMs were incubated with all possible com-
binations of one of the substrates (S-Ibu, R-Ibu, or rac-Ibu) and one of
the cofactors (UDP-GA, UDP-Glc, or UDP-Gal). As expected, sub-
sequent LC-MS analysis revealed that the presence of UDP-GA led to
the generation of Ibu-AGs, which were identified by a m/z value of
381 for [M-H] in negative ion mode (Fig. 1). With all three sub-
strates, samples with UDP-Glc displayed an UV peak containing the
m/z values 403 and 413, which correspond to chlorine [MCl] or
formic acid [MFA-H] adducts of Ibu acyl glycosides. Abundance
values of the extracted ion currents indicate that in samples with both
cofactors (i.e., UDP-GA and UDP-Glc), metabolism of S-Ibu was
faster than that of R-Ibu. It was interesting to note that Ibu-AG was
also present in a very low amount in samples with UDP-Glc (data not
shown), which indicates the presence of a (albeit low) UGDH activity
in the microsome preparation. In samples with UDP-Gal and in
control reactions (without a cofactor), essentially no Ibu metabolites
were detected. A scheme of the glucuronidation and glucosidation
reactions of both Ibu isomers is shown in Fig. 2.
Production of Ibu-AG and Ibu-Glc by Recombinant Fission
Yeast Strains That Overexpress Different Combinations of
UGT2B7 and UGDH. We previously showed that the fission yeast S.
pombe is a suitable organism for the functional expression of human
UGTs (Dragan et al., 2010). Because human UGT2B7 exhibits high
activity toward Ibu (Sakaguchi et al., 2004; Kuehl et al., 2005) and,
moreover, is able to use UDP-Glc as a cofactor for the production of
a glucoside (Tang et al., 2003), we cloned UGT2B7-expressing fission
yeast strains in the study presented here to examine their ability for
Ibu glucosidation. Because the two polymorphic variants UGT2B7*1
and UGT2B7*2 have been shown to possess varying activities against
some substrates (Thibaudeau et al., 2006; Belanger et al., 2009), we
included them both in this work. Fission yeast strain NCYC2036 was
transformed with the expression plasmids pCAD1-UGT2B7*1 and
pCAD1-UGT2B7*2 to yield the new strains DB7 and DB4, respec-
tively (all strains are listed in Table 1). Because (in contrast to
UDP-Glc and UDP-Gal) there is no endogenous UDP-GA production
in S. pombe (Dragan et al., 2010), these two strains lack the potential
of glucuronide formation. For control purposes, both strains were then
transformed with the plasmid pREP1-UGDH (Dragan et al., 2010) to
yield DB17 (from DB7) and DB14 (from DB4). Because UGDH
catalyzes the production of UDP-GA from UDP-Glc, these latter
strains are capable of self-sufficient glucuronide production. In addi-
FIG. 1. Extracted ion currents derived from incubations of HLMs with S-Ibu, R-Ibu, and rac-Ibu with either no UDP-sugar, UDP-GA, UDP-Glc, or UDP-Gal as indicated.
Ibu, [M-H]3 m/z  205; Ibu-AG, [M-H]3 m/z  381; and Ibu-Glc, [MCl]3 m/z  403. All experiments were done in triplicate, and data from one experiment
each are shown exemplarily.
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tion, UGT double-expressing strains were generated by transforma-
tion of strain DB7 with the plasmid pREP1-UGT2B7*1 and of DB4
with the plasmid pREP1-UGT2B7*2, respectively, to yield strains
DB63 and DB62. All newly created strains were used for whole-cell
biotransformation experiments with the substrates S-Ibu, R-Ibu, or
rac-Ibu (Table 2). As expected, the parental strain NCYC2036 did not
produce any Ibu metabolites and the single expressor strains DB4 and
DB7 (containing UGT2B7*2 and UGT2B7*1, respectively) produced
Ibu-Glc but not Ibu-AG because of a lack of UDP-GA. It was
interesting to note that the Ibu-Glc production rates for the different
substrate enantiomers differed significantly, with S-Ibu again being
much more readily converted than R-Ibu. Furthermore, in almost all
cases the two UGT2B7*1 expressing strains showed an almost dou-
bled biotransformation rate as compared with the UGT2B7*2 expres-
sors. In addition, the UGT double-expressing strains DB62 and DB63
did not display enhanced reaction rates in comparison to the parental
single expressing strains DB4 and DB7 (data not shown), indicating
that the intracellular UGT levels were not rate-limiting under these
conditions. In line with expectations, the UGDH coexpressing strains
DB14 and DB17 were able to produce Ibu-AG and Ibu-Glc, and
biotransformation of S-Ibu was again preferred over R-Ibu. However,
there was no consistent picture with respect to the relative formation
of Ibu-AG versus Ibu-Glc, with glucuronide production being pre-
ferred over glucoside production in some instances but not in others.
Identification of the Fission Yeast UGPase fyu1. We speculated
that an increase in intracellular UDP-Glc levels would enhance UGT-
dependent glucoside production by whole-cell biotransformation in
fission yeast. UDP-Glc production depends on UGPases, a family of
enzymes that catalyze the balanced reaction of the formation of
UDP-Glc and pyrophosphate from UTP and glucose-1-phosphate and
that were identified in many organisms (Thoden and Holden, 2007).
In the genome of fission yeast, there are two putative UGPase
homologs with the systematic designations SPCC794.10 and
SPCC1322.04, respectively (Wood et al., 2002). We amplified the
coding sequences of both genes from strain NCYC2036 and cloned
each of them into the expression plasmid pREP1. Strain DB4 was then
transformed with pREP1-SPCC794.10 to obtain strain DB64 and with
pREP1-SPCC1322.04 for strain DB65. In the same way, DB7 was
transformed with pREP1-SPCC794.10 for strain DB66 and with
pREP1-SPCC1322.04 for strain DB67. Thus, these strains each co-
express a human UGT2B7 isoform and one of the two fission yeast
UGPase homologs. Whole-cell biotransformations of these strains
with Ibu (Fig. 3) showed that overexpression of SPCC794.10 did not
lead to an enhanced Ibu-Glc production rate for any of the substrates
in strains DB64 and DB66 as compared with their parental strains
DB4 and DB7, respectively. Thus, these data do not support the notion
that SPCC794.10 is an UGPase. In contrast, overexpression of
SPCC1322.04 led to a significant increase in the production of Ibu-
Glc from S-Ibu by strain DB67 in comparison to the parental strain
DB7, whereas for strain DB65 no enhanced Ibu-Glc production could
be detected (probably because of the weaker activity of UGT2B7*2
for this reaction). These data suggest that only one of the two putative
fission yeast UGPase homologs—SPCC1322.04—indeed displays
this activity. We therefore suggest to name it fyu1 for fission yeast
UGPase 1.
Production of Stable Isotope-Labeled Ibu-AG and Ibu-Glc. The
availability of stable isotope-labeled reference standards is expedient
for the sensitive quantification of metabolites in biological matrices
FIG. 2. Scheme of the glucuronidation and gluco-
sidation reactions of S-Ibu and R-Ibu, respectively.
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by LC-MS and thus facilitates the toxicokinetic monitoring of metab-
olites during nonclinical safety studies. We have previously demon-
strated that cultivation of UGT-expressing fission yeast strains in
media containing [13C6]glucose is a convenient method of producing
13C6-labeled glucuronides (Dragan et al., 2010). In this study, whole-
cell biotransformations were done using the substrate S-Ibu and
strains DB14 and DB17 for the production of S-Ibu-[13C6]AG and
strain DB67 for the production of S-Ibu-[13C6]Glc, respectively
(Fig. 4). The comparison of the LC-MS analysis of the extracted ion
currents of nonlabeled (Fig. 4, a and d) and 6-fold labeled metabolites
(Fig. 4, b and e), as well as the respective fragmentation spectra (Fig.
4, c and f), unambiguously shows the successful formation of S-Ibu-
[13C6]AG and S-Ibu-[13C6]Glc, respectively.
Discussion
Although glucuronide formation is a major reaction in mammalian
phase II metabolism, a significant number of glucoside metabolites
has also been identified, including the O-acyl glucoside of an endo-
thelin ETA antagonist (Tang et al., 2003) and the N-glucoside of
bromfenac (Kirkman et al., 1998). In addition, the formation of bile
acid O-glucosides by human liver microsomes and their occurrence in
human urine has been known for a long time, whereas acyl galacto-
sides of cholic acid and deoxycholic acid were described more re-
cently (Goto et al., 2005). Thus, it was the aim of this study to
investigate the possible formation of acyl glucoside metabolites of
Ibu. Biotransformation experiments with HLMs demonstrated the
production of Ibu-Glc in the presence of the cofactor UDP-Glc (Fig.
1). As expected, Ibu-AG was produced in the presence of UDP-GA,
whereas traces of it could also be detected in all incubations with
UDP-Glc, in two incubations with UDP-Gal and one incubation
without cofactor (out of nine incubations each), respectively. The
detection of Ibu-AG in incubations with UDP-Glc is most likely
caused by remaining UGDH activity in the microsome preparation,
whereas in samples with UDP-Gal detection of Ibu-AG correlated
with that of Ibu-Glc, indicating that in those two samples two further
reactions took place. First, UDP-Gal was converted by UDP-Gal-4-
epimerase to UDP-Glc and subsequently yielded Ibu-Glc; second, part
of the UDP-Glc was converted by UGDH to UDP-GA and allowed
the production of Ibu-AG. Unfortunately, quantitative analysis of the
Ibu-Glc formation was not possible because of further compounds in
the reaction mixture that contributed to the UV signals of the targets
to an unknown extent (data not shown). Still, these data unambigu-
ously demonstrate the conversion of R-Ibu and S-Ibu to their respec-
tive acyl glucosides by human enzymes.
Because it was known that human UGT2B7 can metabolize Ibu
(Sakaguchi et al., 2004; Kuehl et al., 2005) and produce glucosides
from other xenobiotics (Tang et al., 2003), it was reasonable to
assume a participation of this enzyme in Ibu-Glc production. To verify
this assumption, we adapted our previously established UGT expres-
sion system (Dragan et al., 2010) to the functional expression of the
two polymorphic variants UGT2B7*1 and UGT2B7*2. Recombinant
fission yeast strains that express one of these variants were found to
be capable of producing Ibu-Glcs, whereas upon coexpression of
human UGDH production of Ibu-Glcs and Ibu-AGs was observed
(Table 2). The data clearly show a preference of both UGT2B7
isoforms for the isomer S-Ibu as a substrate for glucosidation and
glucuronidation reactions, which is in agreement with previous studies
in which a preferred glucuronidation of S-Ibu was shown in vivo (Lee
et al., 1985; Tan et al., 2002) and for immobilized HLM proteins in
vitro (el Mouelhi et al., 1987). However, to complicate matters, it is
known that a conversion of R-Ibu to S-Ibu is accomplished by 2-aryl-
propionyl-CoA epimerase (Shieh and Chen, 1993; Reichel et al.,
1997). A bioinformatic search did not reveal homologs of this enzyme
in the genome of S. pombe (data not shown), but nevertheless it cannot
be excluded that such a reaction might also occur in fission yeast. In
fact, such an effect might contribute to the rather large S.D. that we
observed in some of the biotransformations. In addition, an endoge-
nous UDP-Gal-4-epimerase homolog has been described (Suzuki et
al., 2010), and thus, a production of ibuprofen acyl galactoside can
also not completely be ruled out, but it appears to be unlikely in view
of the HLM results described above. It is interesting to note that a
comparison of the activities of strains DB14 and DB17 with their
parental strains DB4 and DB7 shows that in most cases the presence
of UDP-GA does not significantly inhibit the Ibu-Glc production rate,
indicating no strong preference of the enzymes for this cofactor. The
one exception to this observation is the production of S-Ibu-Glc by
UGT2B7*1, which upon UGDH coexpression is reduced to less than
half of its former value. In this connection it is interesting to note that
another study even observed a preference for UDP-Glc as a cofactor
for a UGT2B7-dependent glucosidation (Tang et al., 2003). It will be
FIG. 3. Comparison of the Ibu glucosidation activities of fission yeast strains
DB64, DB65, DB66, and DB67 with their parental strains. Data shown were
calculated from at least three independent experiments for each combination of
strain and substrate and S.D. are indicated.
TABLE 2
Ibu-AG and Ibu-Glc formation rates in whole-cell biotransformations using the substrates R-Ibu, S-Ibu, or rac-Ibu and fission yeast strains expressing enzymes as
indicated
S. pombe Strain UGT CofactorGenerating Enzyme
R-Ibu S-Ibu rac-Ibu
Ibu-AG Ibu-Glc Ibu-AG Ibu-Glc Ibu-AG Ibu-Glc
nmol/(gdw  d) nmol/(gdw  d) nmol/(gdw  d) nmol/(gdw  d) nmol/(gdw  d) nmol/(gdw  d)
NCYC 2036 0 0 0 0 0 0
DB4 UGT2B7*2 0 156.7  12.3 0 295.5  20.8 0 226.8  60.8
DB7 UGT2B7*1 0 346.8  28.0 0 559.8  49.6 0 429.6  143.5
DB14 UGT2B7*2 UGDH 77.1  3.0 109.3  42.7 368.1142.4 233.2  65.2 437.7  79.9 141.4  41.0
DB17 UGT2B7*1 UGDH 163.2  46.4 222.2  82.4 679.7393.2 262.9  182.1 389.6  200.6 328.6  62.3
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interesting to see whether more examples of human UGTs preferring
to convert some substrates with other UDP-sugars than UDP-GA will
be presented in the future.
The findings of this study naturally raise the question of the
physiological significance of UGT2B7-dependent acyl glucoside pro-
duction. Although it is, according to current knowledge, less common
than AG formation, acyl glucoside production as such appears to be
relevant for endogenous substances as well as drug molecules (Sta-
chulski, 2011). Furthermore, other groups have demonstrated before
that human UGT2B7 may use UDP-Glc as a cofactor for the in vitro
production of various glucosides (Mackenzie et al., 2003; Tang et al.,
2003; Toide et al., 2004). Microarray data show that there are many
human tissues that express UGDH to various extents (with strong
signals in liver and colon), whereas UGT2B7 is predominantly ex-
pressed in liver and kidney (Yanai et al., 2005; Dezso et al., 2008).
Thus, it is conceivable to envision a metabolic situation in a certain
tissue (e.g., kidney) where there is strong UGT2B7 activity together
with a significant level of UDP-Glc but low availability of UDP-GA.
Such a situation would be expected to favor UGT2B7-dependent
glucoside production. Finally, the example of the N-glucosidation of
the aldose reductase inhibitor (R)-()-2-(4-bromo-2-fluorobenzyl)-
1,2,3,4-tetrahydropyrrolo[1,2-]pyrazine-4-spiro-3-pyrrolidine-1,2,3,
5-tetrone (AS-3201) demonstrated that UGT-dependent glucosida-
tion might even take place in the presence of UDP-GA because some
UGT isoenzymes (including UGT2B7) only catalyzed the glucosida-
tion but not the glucuronidation reaction of this substrate (Toide et al.,
2004). Taken together, all of this evidence may be interpreted in a
way that allows for UGT2B7-dependent acyl glucoside production
as a rather normal physiological process. Whether these metabo-
lites are readily detected in blood or urine samples is another
matter; in contrast to AGs, acyl glycosides do not per se contain an
anion moiety and it is reasonable to assume that the dynamics of
these conjugates differ from those of the respective glucuronides
because in general they should differ in their ligand properties
toward organic anion-transporting polypeptides or multidrug resis-
tance-associated proteins.
FIG. 4. Production of isotope-labeled S-Ibu-AG (a–c) using strain DB14 and stable isotope-labeled S-Ibu-Glc (d–f). Extracted ion currents of LC-MS analysis of a
whole-cell biotransformation with strain DB14 and the substrate S-Ibu show the pseudomolecular ion of unlabeled S-Ibu-AG (a) and of S-Ibu-[13C6] AG (b). The mass
spectrum at retention time t  19.611 min is given in (c). Extracted ion currents of LC-MS analysis of a whole-cell biotransformation with strain DB67 and the substrate
S-Ibu show the chlorine adduct [MCl] of unlabeled S-Ibu-Glc (d) and of S-Ibu-[13C6]Glc (e). The mass spectrum at retention time t  19.817 min is given in f.
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With respect to Ibu metabolism, the pharmacological potency of the
newly described Ibu-Glcs remains obscure, and it is conceivable that
at least some of the phase I metabolites of Ibu give rise to additional
acyl glucoside metabolites. A prediction of the properties of these
molecules is difficult because it has been recently shown that appar-
ently small changes in the aglycon structure may have unexpected
consequences (Iddon et al., 2011). Therefore, further studies are
needed to investigate the acyl migration, the hydrolysis rate, and the
protein binding capacities of all of these metabolites.
From a biotechnological point of view, efficient metabolite produc-
tion systems are desired to allow for the convenient production of
those metabolites that are tedious to synthesize by chemical means
(Zo¨llner et al., 2010). For the purpose of enhancing UGT2B7 bio-
transformation activity in our whole-cell system, we first constructed
fission yeast strains that harbor two UGT expression units; however,
the use of these strains did not lead to an increase in product formation
as compared with the parental single-expressing strains DB4 and DB7
(data not shown). However, it stood to reason that an increase in
intracellular UDP-Glc levels would facilitate UGT-dependent gluco-
side production. In principle, this aim might be pursued either by
coexpression of a foreign (e.g., human) UGPase or by overexpression
of an endogenous UGPase. In this study it was decided to attempt the
latter because two putative UGPase homologs of fission yeast had
already been identified by the S. pombe genome sequencing project
(Wood et al., 2002). Expression plasmids containing either one of the
two sequences were cloned and used to transform strains that recom-
binantly express UGT2B7*1 or UGT2B7*2, respectively, to yield the
new strains DB64 to DB67 (Table 1). It was observed that one of two
proteins—which we suggest to name fyu1—was able to significantly
enhance the Ibu-Glc reaction rate, albeit only in combination with
UGT2B7*1 (Fig. 3). This result suggests that, in addition to cofactor
availability, UGT2B7 polymorphisms also influence the production
rate of glucosides. It would be interesting to purify both proteins and
determine their cofactor binding kinetics; however, these experiments
were out of the scope of the study presented here. Still, it can be
predicted that such an analysis will result in marked differences
between the two variants.
Because the availability of stable isotope-labeled metabolites is
desirable for the LC-MS analysis of biological matrices, we used our
previously established general labeling technique (Dragan et al.,
2010) using [13C6]glucose as a metabolic precursor that is efficiently
converted within the fyu1 expressing fission yeast strains to 13C6-
labeled UDP-Glc, which in turn serves as the cofactor for the
UGT2B7-dependent production of S-Ibu-[13C6]Glc (Fig. 4). Likewise,
when using UGDH-expressing fission yeast strains, [13C6]glucose is
converted to 13C6-labeled UDP-GA and thus allows for the formation
of S-Ibu-[13C6]GA. It is expected that the availability of these stable
isotope-labeled metabolites will be helpful for further studies in this
direction.
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 Abstract 
 Human UDP glycosyltransferases (UGTs) play an important 
role in xenobiotic detoxifi cation. They increase the solubility 
of their substrates by adding a sugar moiety (such as glucuronic 
acid) to different functional entities (such as hydroxyl groups). 
The aim of this study was to investigate how glucuronidation 
of a standard substrate is affected by a change of the hetero-
atom at the conjugation site. For this purpose, we compared 
the  in vitro glucuronidation rates of 4-methylumbelliferone 
and 7-mercapto-4-methylcoumarin, respectively. Human liver 
microsomes catalyzed the  S -glucuronidation of 7-mercapto-4-
 methylcoumarin almost as effi cient as the  O -glucuronidation 
of 4-methylumbelliferone. When testing isoenzyme specifi city 
by whole cell biotransformation with fi ssion yeast strains that 
recombinantly express all 19 human members of the UGT1 
and UGT2 families, it was found that 13 isoenzymes were able 
to glucuronidate 7-mercapto-4-methylcoumarin, with fi ve of 
them being specifi c for this substrate and the other eight also 
converting 4-methylumbelliferone under these conditions. 
The remaining six UGTs did not accept either substrate. Out 
of the eight isoenzymes that glucuronidated both substrates, 
four catalyzed both reactions approximately to the same 
extent, while three displayed higher conversion rates towards 
4-methylumbelliferone and one preferred 7-mercapto-
4-methylcoumarin. These data suggest that 7-mercapto-4-
methylcoumarin is a convenient new standard substrate for 
monitoring  S -glucuronidation. 
 Keywords:  coumarin;  fi ssion yeast;  S-glucuronide;  thiol; 
 UGT;  whole cell biotransformation. 
 Introduction 
 Human uridine diphospho glycosyltransferases (UGTs) 
are a class of enzymes that is best known for catalyzing the 
transfer of glucuronic acid from uridine diphosphate (UDP) 
glucuronic acid (UDPGA) to xenobiotics as well as endoge-
nous substrates, thereby increasing their hydrophilic properties 
and facilitating their elimination from the body (Bock , 2010 ; 
Guillemette et al. , 2010 ). This function makes them the main 
enzymes of phase II metabolism, a role illustrated by the fact 
that they contributed to the clearance of approximately 10 % 
of the top 200 drugs prescribed in the USA in 2002 (Williams 
et al. , 2004 ). UGT homologs have been identifi ed in mam-
mals, fi sh, worm, viruses, yeast, plants, bacteria and insects 
(Mackenzie et al. , 1997 ; Bock , 2003 ). In humans, there are 
four UGT families (UGT1, UGT2 with subfamilies A and 
B, UGT3, and UGT8, respectively) with a total of 22 single 
isoforms. The 19 members of the UGT1 and UGT2 families 
typically prefer UDPGA as cofactor and are therefore often 
referred to as UDP-glucuronosyltransferases (Bock , 2003 ; 
Mackenzie et al. , 2005 ). Human UGT3A1 recently has been 
shown to perform  N -acetylglucosaminidations (Mackenzie 
et al. , 2008 ) and UGT3A2 uses UDP-glucose and UDP-xylose 
as cofactor for the conjugation of both endogenous and exog-
enous substrates (Meech and Mackenzie , 2010 ; Mackenzie 
et al. , 2011 ). UGT8 uses UDP-galactose to catalyze the syn-
thesis of galactosylceramide (Bosio et al. , 1996 ). The known 
substrates of the human UGTs that participate in phase II 
metabolism are structurally very diverse and, moreover, 
the sugar moieties may be transferred to multiple functional 
sites, such as amine, carbonyl, carboxyl, hydroxyl, and thiol 
groups (Tukey et al. , 2000 ); even  C -glucuronides have been 
reported, although rarely (Richter et al. , 1975 ; Kerdpin et al. , 
2006 ). Although thiol groups are not a very rare occurrence 
in drug compounds, the number of reports on  S -glucuronides 
is limited. Some examples are the metabolites of dalcetrapib 
(Kuhlmann and Heinig , 2011 ), HMR1098 (Ethell et al. , 2003 ), 
AR-C133611XX (Martin et al. , 2003 ), 2-mercaptobenzothiaz-
ole (Fukuoka et al. , 1995 ) or malotilate (Nakaoka et al. , 1989 ). 
A study aimed at the identifi cation of UGT isoforms responsible 
for a specifi c  S- glucuronidation reaction showed that all of the 
four tested candidates (UGT1A1, 1A9, 1A6, and 2B7, respec-
tively) were able to catalyze it, although at signifi cantly varying 
rates (Ethell et al. , 2003 ), thus indicating that  S -glucuronidation 
is not a specifi c function performed by a single UGT isoenzyme. 
However, a systematic approach involving all 19 members of 
the human UGT1 and UGT2 families had not yet been done. It 
was the aim of this study to compare the  O -glucuronidation of 
the standard substrate 4-methylumbelliferone (4MU) with the 
 S -glucuronidation of its thiol analog 7-mercapto-4-methylcou-
marin (7M4MC; Figure 1). For this purpose, we used human 
liver microsomes (HLMs) and recombinant fi ssion yeast 
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strains that co-express human UDP glucose dehydrogenase 
(UGDH) and one of the 19 human UGTs, and we demonstrate 
that the majority of human UGTs are capable of catalyzing the 
 S -glucuronidation of 7M4MC. 
 Results 
 Glucuronidation of 4MU and 7M4MC by human 
liver microsomes 
 For a global comparison, glucuronidation activity of HLMs 
towards either 4MU or 7M4MC was monitored in the pres-
ence of UDPGA. 4MU of course is a standard UGT sub-
strate (Uchaipichat et al. , 2004 ) and its biotransformation 
to 4MU glucuronide (4MUG) proceeded effi ciently with 
a total conversion of 99.3 ± 0.1 % under the test conditions. 
The thiol analog of 4MU, 7M4MC, was also effi ciently 
glucuronidated; the product gave an absorption peak at 
320  nm which contained the mass for the pseudomolecular 
ion [M-H] - of 7M4MC glucuronide (7M4MCG),  m/z = 367 
(Figure  2 ). Using the same conditions, the total turnover 
was 82.3 ± 1.3 % . When using the alternative cofactors UDP 
glucose or UDP galactose instead of UDPGA, the formation 
of reaction products was also observed (data not shown), but 
this line of investigation was not pursued further. 
 Glucuronidation of 7M4MC using recombinantly 
expressed human UGTs 
 Having established that at least some human UGTs are able to 
glucuronidate 7M4MC, we next sought to identify the relevant 
isoforms. We recently reported the construction of an effi cient 
UGT expression system using recombinant fi ssion yeast of the 
species  Schizosaccharomyces pombe , which is based on the 
co-expression of human UGDH (which produces the essential 
cofactor UDPGA not present in wild-type fi ssion yeast) and 
UGT enzymes (Dragan et al. , 2010 ). So far, we reported the 
functional expression of ten human and one rat UGT isoform 
using this system (Dragan et al. , 2010 ; Buchheit et al. , 2011 ). 
In this study, the remaining nine members of the human 
UGT1 and UGT2 families (UGT1A3, UGT1A4, UGT1A5, 
UGT2A2, UGT2A3, UGT2B4, UGT2B10, UGT2B11, and 
UGT2B28, respectively) were also expressed in fi ssion yeast 
(all strains are listed in Table  1 ). The glucuronidation activ-
ity of all 19 UGT isoforms towards the substrates 4MU and 
7M4MC was determined by whole cell biotransformation at 
shaking fl ask scale and subsequent HPLC analysis (Table  2 ). 
For strains showing glucuronide formation, product identity 
 Figure 1  Compounds used in this study. 
was confi rmed by LC-MS analysis. In nine cases, 4MUG pro-
duction rates had already been reported previously as indi-
cated (Dragan et al. , 2010 ). Six out of 19 UGT isoenzymes 
did not accept either substrate under these conditions, eight 
UGTs metabolized both and fi ve converted only one sub-
strate, 7M4MC. Thus, a total of 13  S -glucuronidation and 
eight  O -glucuronidation reactions were observed, respec-
tively. To the best of our knowledge, these data make 7M4MC 
one of the most widely accepted human UGT substrates 
described to date. For both substrates, biotransformation rates 
varied signifi cantly from less than 0.1 to more than 5  µ mol/
(g dw × d), an observation that correlates well with previous 
data on 4MU glucuronidation activities of different human 
UGT isoenzymes (Uchaipichat et al. , 2004 ). Out of the eight 
isoenzymes that did work on both substrates, three displayed 
higher conversion rates towards 4MU, while one acted faster 
on 7M4MC and four catalyzed both reactions approximately 
to the same extent. 
 Generation of stable isotope labeled 7M4MCG 
 By use of [ 13 C] 6 -labeled glucose, we previously demonstrated 
the production of stable isotope labeled  O -glucuronides, 
with the sugar moiety being either attached to a hydroxyl 
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 (A) HPLC chromatogram of an incubation of HLMs with the sub-
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 Table 1  Fission yeast strains used in this study. 
Strain Parental strain Expressed protein(s) Genotype Reference
NCYC2036  –  –  h -  ura4-D18 (Losson and Lacroute , 1983 )
DB21 NCYC2036 UGT1A3  h -  ura4-D18 leu1::pCAD1-UGT1A3 This study
DB2 NCYC2036 UGT1A4  h -  ura4-D18 leu1::pCAD1-UGT1A4 This study
DB22 NCYC2036 UGT1A5  h -  ura4-D18 leu1::pCAD1-UGT1A5 This study
DB27 NCYC2036 UGT2A2  h -  ura4-D18 leu1::pCAD1-UGT2A2 This study
DB28 NCYC2036 UGT2A3  h -  ura4-D18 leu1::pCAD1-UGT2A3 This study
DB29 NCYC2036 UGT2B4  h -  ura4-D18 leu1::pCAD1-UGT2B4 This study
DB30 NCYC2036 UGT2B10  h -  ura4-D18 leu1::pCAD1-UGT2B10 This study
DB31 NCYC2036 UGT2B11  h -  ura4-D18 leu1::pCAD1-UGT2B11 This study
DB34 NCYC2036 UGT2B28  h -  ura4-D18 leu1::pCAD1-UGT2B28 This study
DB11 DB1 UGT1A1, UGDH  h -  ura4-D18 leu1::pCAD1-UGT1A1/pREP1-UGDH (Dragan et al. , 2010 )
DB41 DB21 UGT1A3, UGDH  h -  ura4-D18 leu1::pCAD1-UGT1A3/pREP1-UGDH This study
DB12 DB2 UGT1A4, UGDH  h -  ura4-D18 leu1::pCAD1-UGT1A4/pREP1-UGDH This study
DB42 DB22 UGT1A5, UGDH  h -  ura4-D18 leu1::pCAD1-UGT1A5/pREP1-UGDH This study
DB43 DB23 UGT1A6, UGDH  h -  ura4-D18 leu1::pCAD1-UGT1A6/pREP1-UGDH (Dragan et al. , 2010 )
DB44 DB24 UGT1A7, UGDH  h -  ura4-D18 leu1::pCAD1-UGT1A7/pREP1-UGDH (Dragan et al. , 2010 )
DB45 DB25 UGT1A8, UGDH  h -  ura4-D18 leu1::pCAD1-UGT1A8/pREP1-UGDH (Dragan et al. , 2010 )
CAD203 CAD200 UGT1A9, UGDH  h -  ura4-D18 leu1::pCAD1-UGT1A9/pREP1-UGDH (Dragan et al. , 2010 )
DB46 DB26 UGT1A10, UGDH  h -  ura4-D18 leu1::pCAD1-UGT1A10/pREP1-UGDH (Dragan et al. , 2010 )
DB13 DB3 UGT2A1, UGDH  h -  ura4-D18 leu1::pCAD1-UGT2A1/pREP1-UGDH (Dragan et al. , 2010 )
DB47 DB27 UGT2A2, UGDH  h -  ura4-D18 leu1::pCAD1-UGT2A2/pREP1-UGDH This study
DB48 DB28 UGT2A3, UGDH  h -  ura4-D18 leu1::pCAD1-UGT2A3/pREP1-UGDH This study
DB49 DB29 UGT2B4, UGDH  h -  ura4-D18 leu1::pCAD1-UGT2B4/pREP1-UGDH This study
DB17 DB7 UGT2B7, UGDH  h -  ura4-D18 leu1::pCAD1-UGT2B7/pREP1-UGDH (Buchheit et al. , 2011 )
DB50 DB30 UGT2B10, UGDH  h -  ura4-D18 leu1::pCAD1-UGT2B10/pREP1-UGDH This study
DB51 DB31 UGT2B11, UGDH  h -  ura4-D18 leu1::pCAD1-UGT2B11/pREP1-UGDH This study
DB52 DB32 UGT2B15, UGDH  h -  ura4-D18 leu1::pCAD1-UGT2B15/pREP1-UGDH (Dragan et al. , 2010 )
DB53 DB33 UGT2B17, UGDH  h -  ura4-D18 leu1::pCAD1-UGT2B17/pREP1-UGDH (Dragan et al. , 2010 )
DB54 BD34 UGT2B28, UGDH  h -  ura4-D18 leu1::pCAD1-UGT2B28/pREP1-UGDH This study
(Dragan et al. , 2010 ) or a carboxyl group (Buchheit 
et al. , 2011 ). In the present study, we wanted to confi rm 
that a similar strategy can also be used for the production 
of labeled  S -glucuronides. For this purpose, fi ssion yeast 
strain CAD203 was used in a whole cell biotransformation 
of 7M4MC at miniaturized scale. LC-MS analysis of the 
extracted ion currents of unlabeled (Figure  3 A) and 6-fold 
labeled metabolites (Figure  3 B), as well as the respective 
fragmentation spectra (Figure  3 C), clearly show the suc-
cessful formation of 7M4MC[ 13 C] 6 G. 
 Discussion 
 Thiols are chemically and biochemically very active func-
tional groups that, among other reactions, easily undergo oxi-
dation in the presence of an electron acceptor to form sulfenic, 
sulfi nic, and fi nally sulfonic acids or disulfi des. Despite these 
properties, active pharmaceutical compounds that comprise 
thiol functions are not uncommon: cysteamine, tiopronin, 
 d -penicillamine, captopril, mesna,  N -acetylcysteine, thy-
reostats, and thiopurines are some of the most important 
examples. During phase II metabolism, thiol groups may be 
converted into  S -glucuronides by UGT enzymes. Moreover, 
other sulfur functions may also yield  S -glucuronides, either 
after prior phase I reactions or by direct conjugation, as in 
the case of the thiones AR-C133611XX (Martin et al. , 2003 ) 
and tanaproget, where the  S -glucuronide actually is a major 
metabolite (Keating et al. , 2006 ). In addition, there are tet-
rahydrothienopyridine antithrombotic prodrugs (such as 
ticlopidine, clopidogrel, and prasugrel) that are intended to 
be metabolized  in vivo into pharmacologically active thiol 
derivatives (Dansette et al. , 2010 ). Thus, while conjugation 
reactions that take place at hydroxyl groups will almost cer-
tainly continue to receive most attention, the phase II metab-
olism of thiol groups is also of interest. It was the purpose 
of this study to compare the UGT-dependent glucuronida-
tion of the well-known standard UGT substrate 4MU with 
its thiol analog 7M4MC (Figure  1 ). We fi rst investigated the 
glucuronidation activity of HLMs towards both substrates 
and observed that they are metabolized with roughly compa-
rable effi ciency (Figure  2 ). Skellern and coworkers published 
a somewhat similar study almost 20  years ago, comparing 
the glucuronidation of 4-nitrophenol and 4-nitrothiophe-
nol by guinea pig liver microsomes and observing that the 
 S -glucuronidation reaction was signifi cantly slower than the 
 O -glucuronidation (Smith et al. , 1992 ). Both studies show 
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in a given compound does not preclude its glucuronidation 
but affects its rate of metabolism. Interestingly, in this study 
additional HLM experiments using the alternative cofac-
tors UDP glucose or UDP galactose instead of UDPGA also 
indicated product formation with both substrates (data not 
shown). However, the investigation of glucoside and galac-
toside formation from 4MU or 7M4MC was out of the scope 
of the present study and thus no further experiments were 
done in this direction. 
 For the identifi cation of the UGT isoforms that participate 
in 7M4MC glucuronidation, we made use of our recently 
established fi ssion yeast system (Dragan et al. , 2010 ). The 
existing set of ten human UGTs functionally expressed in 
this system was expanded by nine further isoenzymes to now 
encompass all 19 human members of the UGT1 and UGT2 
families (Table  1 ). Somewhat surprisingly, the determination 
of the glucuronidation activity of all isoforms towards the sub-
strates 4MU and 7M4MC revealed that the latter coumarin is 
actually metabolized by more human UGTs than the former 
(Table  2 ). More specifi cally, seven out of nine members of 
the UGT1 family, all three members of the UGT2A subfamily 
and three of the seven UGT2B isoforms were found to cata-
lyze this  S -glucuronidation reaction. In these experiments, not 
a single human UGT that acted on 4MU did not convert its 
thiol analog, although three displayed higher conversion rates 
towards the substrate with the hydroxyl group; one isoform 
 Table 2  Biotransformation of 4MU and 7M4MC by recombinant 
 Schizosaccharomyces pombe strains. 
Strain UGT Product formation
4MU 7M4MC
MB163 None  –  – 
DB11 UGT1A1  + a  + + 
DB41 UGT1A3  –  + 
DB12 UGT1A4  –  – 
DB42 UGT1A5  –  – 
DB43 UGT1A6  + + a  + 
DB44 UGT1A7  + + + a  + + + 
DB45 UGT1A8  + + + a  + + + 
CAD203 UGT1A9  + + + + a  + + + 
DB46 UGT1A10  + + + a  + + + 
DB13 UGT2A1  + + + + a  + + 
DB47 UGT2A2  –  + 
DB48 UGT2A3  –  + 
DB49 UGT2B4  –  – 
DB17 UGT2B7  –  + 
DB50 UGT2B10  –  – 
DB51 UGT2B11  –  – 
DB52 UGT2B15  + + a  + + 
DB53 UGT2B17  – a  + 
DB54 UGT2B28  –  – 
 
a
 Data from Dragan et al.  (2010) .  – , no product detected;  + , product 
formation rate below 0.1  µ mol/(g dw × d);  + + , product formation rate 
between 0.1 and 0.5  µ mol/(g dw × d);  + + + , product formation rate 
between 0.5 and 5  µ mol/(g dw × d);  + + + + , product formation rate 
above 5  µ mol/(g dw × d). 
showed the opposite preference and four catalyzed both reac-
tions equally well. 
 It must be noted that the failure of some of UGT iso-
forms to glucuronidate 4MU in our system is at variance 
to earlier studies from other groups (Levesque et al. , 2001 ; 
Uchaipichat et al. , 2004 ; Barre et al. , 2007 ; Sneitz et al. , 
2009 ). However, the data from the literature are also not 
consistent in all cases, and differences in experimental setup 
or assay conditions might be critical if very small activities 
are to be detected. 
 As expected, our whole cell biotransformation system 
could also be utilized for the production of a stable isotope-
labeled  S- glucuronide from [ 13 C] 6 -labeled glucose (Figure  3 ), 
as shown previously for similarly labeled  O- glucuronides 
and  O -glucosides, respectively (Dragan et al. , 2010 ; Buchheit 
et al. , 2011 ). Other stable isotope-labeled  S -glucuronides of 
drug compounds or candidates should be producible in the 
same way, and the availability of such standards should be 
helpful for the LC-MS analysis of drug metabolites in bio-
logical matrices. 
 As described above, there is no common tendency when 
comparing the  O - and  S -glucuronidation activities of the 
different UGT isoforms in this study. Considering the UGT 
reaction mechanism, this observation is somewhat surprising. 
Because acceptor- β - d -glucuronides are built from UDP- α -
 d -glucuronic acid, the catalysis mechanism of glucuronida-
tion is assumed to be a S N 2 reaction. It is proposed that a base 
deprotonates the functional group at the site of glucuronida-
tion, e.g. a -OH or -SH group, which increases the nucleo-
philicity of the charged heteroatom. This in turn performs a 
nucleophilic attack on the anomeric carbon of the glucuronic 
acid from UDPGA, which results in glucuronide formation 
(Ouzzine et al. , 2003 ). The elements sulfur and oxygen 
are neighbors in the chalkogen group and therefore have 
somewhat similar physical properties. However, in general, 
sulfur has higher nucleophilicity because of its large size, 
which makes it more polarizable, and its lone pairs of elec-
trons are readily accessible. Therefore, it could be specu-
lated that the glucuronidation of a thiol group may be more 
likely than that of a hydroxyl group at the same position of 
a molecule. Even if this reasoning is not correct, one might 
at least assume that the replacement of one function by the 
other in a given molecule (as was done here) would affect 
its UGT-dependent biotransformation by all isoforms in the 
same way. However this was not observed, the data rather 
suggest that an extrapolation of the known glucuronidation 
activity towards a hydroxyl group in a given target molecule 
to a thiol group at the same position (or vice versa) is not 
possible. 
 It would be interesting to expand the approach of the present 
study by introducing further functional groups in the 7-position 
of 4-methylcoumarin, such as an amino group. Preliminary 
experiments in our lab showed that 7-amino-4-methylcou-
marin is also metabolized by HLMs to its  N -glucuronide, 
although to a signifi cantly lesser extent than 4MU or 7M4MC 
(data not shown). Lewis and coworkers reported that an 
exchange of a thione group in the CXCR2 receptor antagonist 
AR-C133611XX by an amino group completely eliminated 
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the previously effi cient glucuronidation reaction (Martin et al. , 
2003 ). Therefore, the replacement of a hydroxyl group by an 
amine function will probably have a more pronounced signifi -
cant effect on glucuronidation than in the case of a thiol group; 
however, more investigations in this direction are needed 
before general conclusions can be drawn. 
 In summary, we here report the generation of the 
 S- glucuronide of 7M4MC using human liver microsomes. 
We further expanded our whole cell biotransformation system 
based on UGT-expressing fi ssion yeast strains to comprise all 
19 human members of the UGT1 and UGT2 families. This 
system was shown in the past to be useful for the produc-
tion of  O- glucuronides (including acyl glucuronides) and 
 O -glucosides, whereas here it was successfully employed for 
the production of a  S- glucuronide and for a comparison of all 
human UGT isoforms in their thiol glucuronidation potential. 
 Materials and methods 
 Chemicals 
 7M4MC and 4MU were from Sigma-Aldrich (St. Louis, MO, USA). 
All other chemicals used were either from Carl Roth (Karlsruhe, 
Germany) or Sigma-Aldrich. Methanol (HPLC grade) was from VWR 
(Leuven, Belgium). 
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 Figure 3  Production of isotope labeled 7M4MC[ 13 C] 6 G using 
strain CAD203. 
 Extracted ion currents of LC-MS analysis show the pseudomolecu-
lar ion of unlabeled 7M4MCG (A) and of 7M4MC[ 13 C] 6 G (B). The 
mass spectrum at  t Ret = 11.586  min is given in (C). 
 In vitro metabolism of 4MU and 7M4MC using HLMs 
 Pooled HLMs (BD Biosciences, New York, NY, USA) were incu-
bated using 4MU or 7M4MC as substrate. The total reaction vol-
ume was 100  µ l. Final concentrations of  in vitro incubations were: 
0.5  mg/ml protein, 50  m m Tris-Cl pH 7.5, 10  m m MgCl 2 and 200  µ m 
substrate. Reactions were started by the addition of 2  m m UDPGA; 
samples were incubated for 18  h at 37 ° C and then mixed with an 
equal volume of acetonitrile. As a negative control incubations with-
out cofactor were done. All experiments were done in triplicates. 
 Coding DNA sequences 
 The cDNA of human UGT1A4 was synthesized by Entelechon GmbH 
(Regensburg, Germany); UGT1A3, UGT1A5, UGT2A2, UGT2A3, 
UGT2B4, UGT2B10, UGT2B11, and UGT2B28, respectively, were 
synthesized by GeneArt GmbH (Regensburg, Germany). All cDNAs 
were optimized for expression in  S. pombe . 
 Media and general techniques 
 We used general DNA manipulating methods as well as media and 
genetic methods for fi ssion yeast as described previously (Sambrook 
and Rusell , 2001 ; Forsburg and Rhind , 2006 ). In addition, we used 
EMM containing 100  g/l glucose for biotransformation assays 
and EMM with 20  g/l [ 13 C] 6 -glucose for the synthesis of isotope 
labeled glucuronides. 
 Construction of expression plasmids and fi ssion 
yeast strains 
 Fission yeast strain construction was done following the strategy de-
scribed previously (Dragan et al. , 2010 ). Briefl y, UGT cDNAs were 
cloned via NdeI and BamH I into the integrative vector pCAD1 
(Dragan et al. , 2005 ), which disrupts the  leu1 gene and contains 
an  ura4 marker. The correctness of all constructs was verifi ed by 
automatic sequencing (MWG-Biotech, Ebersberg, Germany). The 
UGDH expression plasmid pREP1-UGDH has been described in 
the literature (Dragan et al. , 2010 ). The vectors pCAD1 and pREP1 
contain the strong endogenous  nmt1 promotor, which is downregu-
lated by the presence of thiamine in the culture media (Maundrell , 
1990 ). Therefore, transformed cells were grown on EMM dishes 
with 5  µ m thiamine to allow better growth under repressed condi-
tions. All strains used in this study are listed in Table  1 . The newly 
created pCAD1-UGT plasmids were used to transform the paren-
tal  S. pombe strain NCYC2036 (Losson and Lacroute , 1983 ) as 
described previously (Suga and Hatakeyama , 2005 ) to yield strains 
DB2, DB21, DB22, DB27, DB28, DB29, DB30, DB31, and DB34, 
respectively. Correct integration into the  leu1 locus was verifi ed by 
selection of leucine auxotrophs on EMM dishes containing 5  µ m 
thiamine without leucine. Subsequently, these new strains contain-
ing an integrated UGT expression cassette were each transformed 
as described previously (Okazaki et al. , 1990 ) with pREP1-UGDH 
to yield strains DB12, DB41, DB42, DB47, DB48, DB49, DB50, 
DB51, and DB54, respectively, to yield UGT and UGDH co-ex-
pressing strains. 
 Biomass production 
 Liquid cultures were prepared as described previously (Dragan et 
al. , 2010 ). Main cultures were incubated for 1  day in the case of 
NCYC2036 and for 4 – 5  days in the case of the UGT and UGDH 
co-expressing strains. 
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 Whole cell biotransformation assay 
 Whole cell biotransformation assays were done as described previ-
ously (Dragan et al. , 2010 ) using the substrates 4MU or 7M4MC as 
indicated at a fi nal concentration of 500  µ m . After the reaction, cul-
ture samples were frozen if necessary until sample preparation and 
analysis. All experiments were done in triplicates. 
 Sample preparation 
 Supernatants from cell suspensions from whole cell biotransforma-
tions with 4MU as substrate were thawed if frozen and centrifuged 
(10  min, 10 000  g , RT) and the supernatants were analyzed by HPLC. 
Cell suspensions from whole cell biotransformations with 7M4MU 
as substrate were thawed if frozen and diluted with 1:1 acetonitrile. 
Samples were centrifuged (5  min, 15 000  g , RT), the supernatant was 
centrifuged again (10  min, 15 000  g , RT), and the resulting superna-
tants were analyzed by HPLC and LC-MS. 
 Synthesis of isotope-labeled glucuronide metabolites 
 The synthesis of isotope-labeled 7M4MC[ 13 C] 6 G was done as de-
scribed in the literature (Buchheit et al. , 2011 ) using the strain 
CAD203. Experiments were done in triplicates. 
 HPLC analysis 
 Analysis of 4MU and 4MUG was done as described in the litera-
ture (Dragan et al. , 2010 ). For analysis of 7M4MC and 7M4MCG, 
a gradient using 0.1 % acetic acid (A) and methanol (B) as mobile 
phases was used as follows. The initial mobile phase composition 
was 85 % A and 15 % B. B was increased linearly to 80 % from 5 to 
10  min, maintained for 4  min until initial conditions were reconsti-
tuted at 14  min. Those were maintained again until the end of the run 
at 18  min. The eluents were monitored at 320  nm. Quantifi cation of 
7M4MCG was done using a straight calibration line of 4MUG, pre-
pared in a 1:1 mixture of mobile phase components (concentrations 
from 10 to 250  µ m 4MUG). 
 Liquid chromatography mass spectrometry 
 7M4MC(G) samples were analyzed on an Agilent 1100 HPLC 
equipped with a G1315B diode array detector (DAD) and a G1946A 
single quadrupole mass spectrometer (MS). Components were sepa-
rated on a Lichrospher RP 18 column (particle size 5  µ m, column inner 
diameter 4  mm, length 125  mm) using water (mobile phase A) and 
methanol containing 0.1 % formic acid (mobile phase B). The fl ow rate 
was 0.8  ml/min and the column temperature was 40 ° C. LC-MS set-
tings were: fl ow profi le 0  min to 6  min, 10 % B, 6  min to 12  min, 10 % 
to 90 % B, 12  min to 17  min, 90 % B, 17  min to 22  min, 10 % B; run-
time 22  min; injection volume 10  µ l; detector 1 G1315B DAD, DAD 
range 200  nm to 600  nm, slit width 4  nm; detector 2 G1946A MSD, 
ionization ESI(-), mode scan; N 2 fl ow rate 12 l/min, nebulizer pres-
sure 45  psig (0.07  bar), nebulizer temperature 350 ° C, capillary voltage 
3.500  V, fragmentor voltage 50  V for 7M4MC(G). Quantifi cation of 
labeled 7M4MCG was done using an external 100  µ m 4MUG standard 
prepared in a 1:1 mixture of mobile phase components. 
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4 Conclusions 
UGTs are important enzymes for the detoxification and excretion of foreign compounds. 
The existence of active or disproportionate metabolites and a demand for reference 
standards require suitable glucuronide production technologies. Existing methods have 
their individual restrictions. A new system for the production of glucuronide was 
developed before the beginning of this work. It is based on fission yeast cells which 
recombinantly coexpress human UGT1A9 and human UGDH. Intact cells were shown to 
be able to produce UGT products in whole-cell biotransformations. In this work, for each 
of the remaining 18 human UGT isoforms as well as rat UGT1A7 a fission yeast expression 
strain was generated. Following pretests of the prior study using UGT1A9, yeast strains 
were generated with a single integrated gene copy of the UGT gene and multiple copies 
of UGDH on an autosomal plasmid. Applying this strain construction strategy which had 
been shown to result in high glucuronide production rates, the parental strain NCYC2036 
(Losson and Lacroute, 1983) was at first transformed with one of the different UGT genes. 
Targeted integration of this first expression unit into the leu1 locus yielded a selection 
marker for a second transformation of the resulting strains with an expression plasmid 
carrying the UGDH gene. For UGT2B7, the two main polymorphic variants (UGT2B7*1: 
H268; UGT2B7*2: Y268) were used in the yeast system due to several reasons; (I) UGT2B7 
is one of the most important UGTs for drug metabolism (Williams et al., 2004), (II) the 
two polymorphic variants are distributed almost 50:50 in Caucasians (Bhasker et al., 
2000) and (III) the polymorphic variants have been shown in several instances to have 
discrete glucuronidation rates (Bernard et al., 2006; Thibaudeau et al., 2006; Belanger et 
al., 2009). Therefore, it was interesting to have both enzymes available in the yeast 
system for comparison studies. A first publication introduced this new system based on 
the initial study using UGT1A9 performed by Călin-Aurel Drăgan and described the 
functional expression of a total of nine human and one rat UGT isoforms in fission yeast 
and the production of glucuronides by whole-cell biotransformations (Dragan et al., 
2010). Until the end of this work, the functional expression of 15 out of 21 isoforms in 
fission yeast could be shown. The previous assumption that UDP-GA is not present in 
fission yeast could be confirmed by the fact that no glucuronide production was observed 
with strains expressing only a UGT isoform and no UGDH. Interestingly, cell growth is 
significantly inhibited by the expression of UGDH, maybe due to the removal of the 
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pivotal compound UDP-Glc. β-glucuronidase is a counter-player of UGTs as it catalyzes the 
cleavage of glucuronides (Bock and Kohle, 2009). Whole-cell biotransformations with the 
parental strain NCYC2036 and 4-methylumbelliferyl-glucuronide as substrate did not lead 
to the appearance of 4-methylumbelliferone, indicating that – as expected – no 
endogenous β-glucuronidase homolog is present in fission yeast (data not shown). The 
lack of activity in fission yeast of so far six UGTs probably is due to the lack of appropriate 
substrates tested. However, during these studies, substrates for at least UGT1A4 were 
tested, which did not lead to a significant glucuronidation by the respective fission yeast 
strain (traces close the detection limit could be detected). However, some of those 
substrates were efficiently converted in our lab by cell lysates from UGT1A4 expressing 
insect cells (expressing the same UGT1A4 coding sequence; data not shown). These data 
indicate that the fission yeast system also seems to have its disadvantages. UGT1A4 may 
be posttranslationally modified in a way which may not be accomplished by fission yeast; 
or the fission yeast cell wall may be not passable by certain compounds (Tanaka et al., 
2001). Interestingly, the substrates used in those experiments carried tertiary amines as 
functional groups for glucuronidation. One could speculate that the charged quarternary 
N+-glucuronide was not able to leave the yeast cell. Still, substantial drawbacks of other 
biological glucuronide production systems could be bridged by the glucuronide 
production system with S. pombe. One major advantage is the ability of a self sufficient 
glucuronidation reaction by the endogenous production of the essential cofactor UDP-
GA. Thus, experiments using living animals may be avoided. As fission yeast only has two 
endogenous CYPs, which are expected to act on steroids (Wood, 2002), background 
metabolism by other DMEs is expected to have only a minor impact, if any, on the 
production of UGT metabolites. The scale up of fission yeast cells is easy to accomplish 
and isoform specific metabolites can be generated. In addition, encouraging results were 
obtained when testing for the production of different glucuronide types. S. pombe was 
shown to be suitable for the production and release of the alkyl O-glucuronides of 
testosterone or 11-α-hydroxyprogesterone, the aryl O-glucuronides of 4-
methylumbelliferone, umbelliferone or 1-naphtol, the acyl glucuronide and glucoside of 
ibuprofen, and the S-glucuronide of 7-thio-4-methylcoumarin, respectively (Dragan et al., 
2010; Buchheit et al., 2011a; Buchheit et al., 2011b). Some of those metabolites were 
additionally produced as 13C6-labelled metabolites (assisted by Ellen Schmitt, under 
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supervision of the author). In contrast, as explained above, for the production of N-
glucuronides so far no glucuronide production could be achieved. The testing of primary 
or secondary amines would be interesting for further studies. Also, the production of an 
N-carbamoyl glucuronide from varenicline was tested (by Ellen Schmitt), unfortunately 
without success. A special attention should be directed to the ability to produce pH-labile 
acyl glucuronides. While in vitro systems in general are incubated in physiological buffer 
at pH 7.4 for glucuronide production, S. pombe decreases the pH value of its medium to 
around 3 or lower. Such low pH values have been shown to stabilize acyl glucuronides 
against degradation (Regan et al., 2010); thus, whole-cell biotransformations with fission 
yeast should provide a suitable environment allowing for the stability of acyl 
glucuronides. Furthermore, this new system could be shown to be applicable for the 
study of UGT enzyme properties, as for the study of UGT substrate preferences or 
cofactor usage. UGTS are known to accept other UDP sugars like UDP-Glc besides UDP-
GA, and UDP-Glc is endogenously present in fission yeast. Fission yeast strains 
coexpressing UGT2B7*1 or UGT2B7*2 with UGDH were shown to be able to glucuronidate 
and to glucosidate S-(+)-ibuprofen and R-(-)-ibuprofen, respectively. Likewise, similar 
strains without UGDH coexpression were able to perform just the glucosidation reactions 
(Buchheit et al., 2011a). Within this study, a so far uncharacterized fission yeast gene could 
be discovered to act as UGPase. A coexpression of this gene, named fyu1 for fission yeast 
UGPase 1, with UGT2B7*1 led to a significant increase of S-(+)-ibuprofen glucoside 
production, which is likely due to an increased intracellular UDP-Glc level. Further studies 
concerning glucosidation properties of the other UGT isoforms are in progress to date. 
The applicability of the fission yeast system for studies concerning the acceptance of 
certain substrates of single UGT isoforms also could be shown. In this study, the ability of 
each UGT and UGDH coexpressing yeast strain for the production of the S-glucuronide of 
7-mercapto-4-methylcoumarin and likewise of the O-glucuronide of 4-
methylumbelliferone was compared (Buchheit et al., 2011b). It could be shown that a 
change of the functional group at the site of glucuronidation from a hydroxyl group to a 
thiol led to a lower amount of glucuronide in assays using human liver microsomes. But 
interestingly, more UGT isoforms were able to catalyze the formation of the S-
glucuronide than the O-glucuronide, albeit with a tendency to lower rates in total. In 
Conclusions 
- 45 - 
 
summary, this system seems to be well suited not only for the production of UGT 
metabolites, but also for the convenient study of UGT enzyme properties. 
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